Gefitinib (ZD1839)

Catalog No.S1025

Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

Price Stock Quantity  
USD 191 In stock
USD 147 In stock
USD 270 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Gefitinib (ZD1839) Chemical Structure

Gefitinib (ZD1839) Chemical Structure
Molecular Weight: 446.90

Validation & Quality Control

Product Use Citation(85)

Customer Product Validation(11)

Quality Control & MSDS

Related Compound Libraries

EGFR Inhibitors with Unique Features

  • Pan EGFR Inhibitor

    AZD8931 (Sapitinib) Pan-ErbB inhibitor, EGFR/ErbB2/ErbB3, IC50=4 nM/3 nM/4 nM.

  • Most Potent EGFR Inhibitor

    Afatinib (BIBW2992) EGFR(wt), IC50=0.5 nM; EGFR(L858R), IC50=0.4 nM; EGFR(L858R/T790M), IC50=10 nM; HER2, IC50=14 nM.

  • FDA-approved EGFR Inhibitor

    Lapatinib Approved by FDA for breast cancer.

  • Newest EGFR Inhibitor

    CO-1686 (AVL-301) Irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.

Product Information

  • Compare EGFR Inhibitors
    Compare EGFR Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.
Targets Tyr1173 (NR6W cells) [1] Tyr1173 (NR6wtEGFR cells) [1] Tyr992 (NR6wtEGFR cells) [1] Tyr992 (NR6W cells) [1]
IC50 26 nM 37 nM 37 nM 57 nM
In vitro Gefitinib effectively inhibits all tyrosine phosphorylation sites on EGFR in both the high and low-EGFR-expressing cell lines including NR6, NR6M and NR6W cell lines. The phosphorylation sites Tyr1173 and Tyr992 are less sensitive requiring higher concentrations of Gefitinib for inhibition. Gefitinib effectively blocks the phosphorylation of PLC-γ, with IC50 of 27nM, in NR6W cells. The NR6wtEGFR and NR6M cell lines has low levels of PLC-γ phosphorylation but the level in the NR6M cell line is more resistant to inhibition by Gefitinib with IC50 of 43 nM and 369 nM, respectively. Gefitinib inhibits Akt phosphorylations, with IC50 of 220 and 263nM, in the low-EGFR- and -EGFRvIII-expressing cell lines, respectively. Gefitinib in the dose range from 0.1 to 0.5μM significantly facilitates, rather than abrogates, colony formation of NR6M cells. However, at a concentration of 2 μM Gefitinib completely blocks NR6M colony formation. Gefitinib rapidly and in a dose-dependent manner inhibits EGFR and ERK phosphorylation up to 72 hours after EGF stimulation in both the high- and low-EGFR-expressing cell lines. [1] Gefitinib is the monolayer growth of these EGF-driven untransformed MCF10A cells with an IC50 of 20 nM. [2] The combination of Gefitinib (0.2 μM and 0.5 μM) with irradiation lead to a significant growth inhibition in LoVo cells, compared with radiation alone.. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
KBMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHu4RY1KSzVyPUCuNFU1KM7:TR?=M{L3bFE3PTF4NEez
NIH3T3NFTtPGVHfW6ldHnvckBCe3OjeR?=NX7DS3FLOC5{IN88US=>MlfqNkBpM4S1N2ROW09?Mlr0TY5pcWKrdHnvckBw\iCHR1[gd5RqdXWuYYTl[EBpfW2jbjDldoJDOSCjdYTvdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjBzNESg{txONXvWZlIyOTZ2OECyPFQ>
COS7MkfmSpVv[3Srb36gRZN{[Xl?M2DNd|k3KM7:TR?=MmqwTY5pcWKrdHnvckBw\iCqdX3hckBLSUt{IG[2NVdHKG23dHHueEBmgHC{ZYPz[YQ>NEL0PW0yPzF5OEeyNi=>
A549MXvDfZRwfG:6aXOgRZN{[Xl?NHuyd|E6PiCqMkHpSG1UVw>?NVfETo13UUN3ME2xN{42QSEQvF2=MYCxPFMyOzhyNx?=
K562NHLQbGVEgXSxdH;4bYMhSXO|YYm=NX2zc2xtQTZiaB?=MWTEUXNQNITYeItKSzVyPUmuN|Yh|ryPMUGxPFMyOzhyNx?=
MDA-MB-231MXjDfZRwfG:6aXOgRZN{[Xl?M{[zO|k3KGh?M{TqZmROW09?NHrQVYtKSzVyPUO2MlYyKM7:TR?=MY[xPFMyOzhyNx?=
MOLT4M1HyXmN6fG:2b4jpZ{BCe3OjeR?=NILtc3M6PiCqMWnEUXNQM2n6bGlEPTB;MUWuNFIh|ryPNIfzTJUyQDNzM{iwOy=>
MCF7NV7QRlJmS3m2b4TvfIlkKEG|c3H5M1HmPFUxKM7:TR?=M3uyVlczKGh?M1H4VWlEPTB;MUKuNFUh|ryPNWLxNpRYOTh5N{G4NVk>
BT474NVzEdpY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlTUO|IhcA>?MlvWRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCEVES3OEBk\WyuczDveoVz\XiycnXzd4lv\yCHUlLiNkB4cXSqIFXDOVAhd2ZiMD6zJO69VQ>?MXKxPVAzQDR{NB?=
HN5MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGjDdm84OiCqM3Pwc2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSF61JINmdGy|IH;2[ZJmgHC{ZYPzbY5oKEWJRmKge4l1cCCHQ{WwJI9nKDBwMEGg{txOM{nDWVE6ODJ6NEK0
BA/F3MkW4R5l1d3SxeHnjJGF{e2G7NYHWbJZ{PzJiaB?=NWTLfox4S3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDFS2ZTKEx6NUjSJI12fGGwdDD3bZRpKEmFNUCgc4YhOC5yMUC4JO69VQ>?M4TVdVE6OjN7MkK5
NIH3T3MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3jXOFczKGh?M{fnSWdzd3e2aDDpcohq[mm2aX;uJI9nKG2xdYPlJG5KUC9|VEOgZ4VtdHNiZYjwdoV{e2mwZzDldmIzKGenbnWge4l1cCCLQ{WwJI9nKDBwNUSg{txOM{O4T|E6PjZ3M{e3
MCF7 MXNIDteZhHfW6ldHnvckBCe3OjeR?=M{PiPFMxKG2rbh?=MkfNTY5pcWKrdHnvckBw\iCEQ2LQJIV5eHKnc4Pl[EB4cXSqIFnDOVAhd2ZiMT6xJO69VQ>?MYmxPVk{Ojl4MB?=
A431NUXHdGhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mly1NVAh|ryPM13uUVczKGh?MVPHTVUxRTBwNUG0JO69VQ>?NVLRVlBCOTl7Nkm0OlU>
A431M2DTRWtqdmG|ZTDBd5NigQ>?NH3xeocxNjFizszNNF\OOHQyKGh?MoHkTY5pcWKrdHnvckBw\iCHR1[tbY5lfWOnZDDFS2ZTKHCqb4PwbI9zgWyjdHnvci=>NGDxWXAyQTl4OUS2OS=>
A431NFPmT4RMcW6jc3WgRZN{[Xl?NYXFcFF2OTByIN88US=>MX[xNEBucW5?MXfQdo9td26pZXSgbY5pcWKrdH;yfUBi[3Srdnn0fUBw\iCHR1[tbY5lfWOnZDDFS2ZTKHCqb4PwbI9zgWyjdHnvci=>NFXVWlYyQTl4OUS2OS=>
Sf9M4DkeWtqdmG|ZTDBd5NigQ>?Ml\ENVAhdWmwM4jp[2ROW09?M3\yV2lvcGmkaYTpc44hd2ZiRVfGVkBmgHC{ZYPz[YQh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBz\WOncITvdkBifXSxcHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlA{OyEQvF2=MnPWNlAxPTZ2MkW=
NCI-H1975MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4XhSVUh|ryPNF3qfI04OiCqMoTRTWM2OD16LkK2JO69VQ>?NF75ZpkzODF3MU[3NC=>
NCI-H1975MWLLbY5ie2ViQYPzZZk>NI\SUoEyOCEQvF2=MWTJcohq[mm2aX;uJI9nKEWJRmKgZZV1d3Cqb4PwbI9zgWyjdHnvci=>M3naZ|IxOTVzNkew
NCI-H1975NYDpT2w{TnWwY4Tpc44hSXO|YYm=M{XiVlExKM7:TR?=M4rVTWlvcGmkaYTpc44hd2ZiRWLCRlIh[XW2b4Doc5NxcG:{eXzheIlwdg>?NWD1e4tsOjBzNUG2O|A>
NCI-H1975MUfGeY5kfGmxbjDBd5NigQ>?NI\2TIg2KM7:TR?=MUm0PEBpM4rKT2lv\HWldHnvckBw\iCjcH;weI9{cXNiYYPz[ZN{\WRiYYOgZYN1cX[jdHnvckBw\iClYYPwZZNmNTN?MXOyNFE2OTZ5MB?=
A375MlHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXnhfIdQPDhiaB?=NWrLeGpkUUN3ME2yNE42PSEQvF2=NVP5N2dSOjB|MES1N|c>
SMMC7721MnnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEjOXoc1QCCqNWnWNYtyUUN3ME2zN{4yOiEQvF2=MoHjNlA{ODR3M{e=
DU145M1XBO2N6fG:2b4jpZ{BCe3OjeR?=NUHYNnlpPSCmMXvEUXNQM1[0U2lEPTB;NEKuNVch|ryPMnHmNlA1PjZ3NUW=
MIAPaCa2NXn2dJJLS3m2b4TvfIlkKEG|c3H5M3fjVlUh\A>?NEHaNGpFVVORMlf5TWM2OD13MD62NkDPxE1?MWqyNFQ3PjV3NR?=
PANC1MlG1R5l1d3SxeHnjJGF{e2G7NIX2VVc2KGR?M1;memROW09?MmTFTWM2OD12MD60NkDPxE1?MliwNlA1PjZ3NUW=
PC9NUPvPXhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG\scmVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGVITlJvZHXmbYNq\W62IHj1cYFvKFCFOTDj[YxteyC5aYToJGVEPTBib3[gNE4xOTdizszNNWfVfVF[OjF{MEi4NFI>
PC9NIHGenZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWftSGI4SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBoem:5dHitdoV{cXO2YX70JIh2dWGwIGDDPUBk\WyuczDlfJBz\XO|aX7nJGVITlJiRUe0On9CPzVyL2S3PVBOKG23dHHueEB4cXSqIFXDOVAhd2ZiNzFOwG0>MX6yNVIxQDhyMh?=
PC3NFLLTHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmjYNVAh|ryPMk\UO|IhcA>?MYDEUXNQNHPTV3FKSzVyPUeuOEDPxE1?MYOyNVM2OzV2Nh?=
MDA-MB-468MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEDEUpcyODBizszNNX[yVVNSPDhiaB?=NWTyWmtxTE2VTx?=NWPGRpBLSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJk>MXyyNVQzQTZ|Mh?=
Plasmodium falciparumM2PI[pFJXFNicILv[oltcW6pIH\vdkBqdmirYnn0c5J{KG:oIGDsZZNud2SrdX2g[oFt[2myYYL1cUBxem:uaX\ldoF1cW:wMX2yNVgyPzB2NR?=
NCI-H1993MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn7CO|IhcA>?MVXEUXNQNW\Heo5vUUN3ME2wMlEh|ryPMXGyNVkyPjR|Mx?=
NCI-H292M3y5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2L6VVczKGh?M1zBcGROW09?MmDWTWM2OD1yLkCyJO69VQ>?NXHVN2lVOjF7MU[0N|M>
A431M1v1NGtqdmG|ZTDBd5NigQ>?NHfhcVYzKGh?NUOwWol4TE2VTx?=MXLJcohq[mm2aX;uJI9nKEWJRmKgdIhwe3Cqb4L5cIF1cW:wIHnuJGVITi2|dHnteYxifGWmIHj1cYFvKEF2M{Gge4l1cCCLQ{WwJI9nKDBwMECxJO69VQ>?M2rSSVIzOTBzMUOy
MCF7NV\Fc3JTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml\LNVAxyqEQvHevcWw>NXHkeY86PDhiaB?=NWXTS3d{TE2VTx?=MXzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNib4\ldoV5eHKnc4PpcochTUeIUjDn[Y5mKHerdHigTWM2OCCxZjCxNk4xPSEQvF2=MnqzNlIyOTlzM{C=
BT474MYDDfZRwfG:6aXOgRZN{[Xl?MoXjNVAh|ryPMWS0PEBpNH\WUYxEgXSxdH;4bYNqfHliYXfhbY5{fCC|ZYL1cU1{fGG{dnXkJIh2dWGwIFLUOFc1KGOnbHzzM{DjZVIzOTN6M{C4
MCF7M2\Mc2N6fG:2b4jpZ{BCe3OjeR?=MkniNVAh|ryPM3zjdFQ5KGh?NG\RclNEgXSxdH;4bYNqfHliYXfhbY5{fCC|ZYL1cU1{fGG{dnXkJIh2dWGwIF3DSlch[2WubIOgc5Zmei2neIDy[ZN{cW6pIFXyZmIzKGOnbHzzM{C0SlIzOTN6M{C4
HCC827Mk\sT4lv[XOnIFHzd4F6NVzuNXpFOC5zMkWg{txONHfKTJEzPCCqMX7EUXNQMn7OTY5pcWKrdHnvckBw\iCHR1\SJIRmdCCHN{S2MWE4PTBibYX0ZY51KFlzME[4JIF2fG:yaH;zdIhwenmuYYTpc44>NUG5[lVUOjJ|M{mzOFI>
HCC827MYrLbY5ie2ViQYPzZZk>NXvsPZNSOC5zMkWg{txOMlPuNlQhcA>?NIraOldFVVORNEjGUlBKdmirYnn0bY9vKG:oIFXHSnIh\GWuIFW3OFYuSTd3MDDteZRidnRvbXXkbYF1\WRiRYLrJJBpd3OyaH;yfYxifGmxbh?=NUXhc2JKOjJ|M{mzOFI>
HCC827NEPKVW9McW6jc3WgRZN{[Xl?NXW1VHh1OC5zMkWg{txOMkXHNlQhcA>?NIX3NmNFVVORMWPJcohq[mm2aX;uJI9nKEWJRmKg[IVtKEV5NE[tRVc2OCCvdYThcpQudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>?NH\QXmszOjN|OUO0Ni=>
A431NHe1U3FMcW6jc3WgRZN{[Xl?MYOxNFAh|ryPNXm1em9COzBibXnuMX3Jcohq[mm2aX;uJI9nKEWJRmKg[IVzcX[nZDDmdo9uKGi3bXHuJGE1OzFiY3XscEBu\W2kcnHu[UBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJBwdHlvR3z1MXR6eiCyaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIEGuNFgh|ryPMoDiNlI3QTh5OEK=
H460MlrxR5l1d3SxeHnjJGF{e2G7MmTaO|IhcA>?NF7jNFZKSzVyPUWuOVkh|ryPNFnWXG4zOjd{N{S0PS=>
HT-29NVfPOJBNS3m2b4TvfIlkKEG|c3H5NVjPWYtPPzJiaB?=M3;ie2lEPTB;Mz6zOkDPxE1?M3yx[|IzPzJ5NES5
SGC7901M1zNeGN6fG:2b4jpZ{BCe3OjeR?=NYD2[oVDPzJiaB?=M1fxfGlEPTB;MUCuNlYh|ryPMUKyNlczPzR2OR?=
A498Mn7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3qxZWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUS5PEBk\WyuczDlfJBz\XO|aX7nJGVITlJiYX7kJHNTSyC5aYToJGlEPTBib3[gPE43KM7:TR?=NUGydXFoOjJ6MUi4OFg>
Calu3MmrNR5l1d3SxeHnjJGF{e2G7M2[1flExKM7:Zz;tUC=>M{G1SFczKGh?MoHiTWM2OD1zLk[g{txOMkPxNlMyOTZzNki=
FADUNELXVYVEgXSxdH;4bYMhSXO|YYm=NWnWPHFtOTBizsznM41NNVrjfppFPzJiaB?=MVvJR|UxRTBwMEWg{txONIfEfY0zOzFzNkG2PC=>
HCC827MWjDfZRwfG:6aXOgRZN{[Xl?MlTjNVAh|rypL33MNEDMXpo4OiCqMVfJR|UxRTBwMECxOUDPxE1?NYT3W4tMOjNzMU[xOlg>
PC9NGW1WWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4\IPFExKM7:Zz;tUC=>NV;uNVlnPzJiaB?=M123OGlEPTB;MD6wNFE1KM7:TR?=MlrPNlMyOTZzNki=
Sf9MWLLbY5ie2ViQYPzZZk>NGjjfG8yKGh?MXrEUXNQM1T0bmlvcGmkaYTpc44hd2ZiaIXtZY4hT1OWLYTh[4dm\CCHR1\SJGw5OzSUIH31eIFvfCCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFAvODF3IN88US=>M{TYUFI{PjFzNkmx
16HBE14o-MkLFR5l1d3SxeHnjJGF{e2G7NGnPfZIyOCEQvF2=NX;MbZV3PzJiaB?=NXToO29{TE2VTx?=MULDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjCxOmhDTTF2bz2gZ4VtdHNiaHHyZo9zcW6pIIfpcIQhfHmyZTDFS2ZTKGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIIfpeIghUUN3MDDv[kAyOi55MTFOwG0>NFvodo8zOzZ4OES0NS=>
NCI-H1975MmP6R5l1d3SxeHnjJGF{e2G7NXHwRoZNOTBizszNNEjwUpo4OiCqMVrEUXNQNVrac5RRS3m2b4TvfIlkcXS7IHHnZYlve3RiZ3XmbZRqdmmkLYLld4l{fGGwdDDoeY1idiCQQ1mtTFE6PzViY3XscJMhcGG{Yn;ybY5oKEWJRmKgUFg2QFJxVEe5NG0h\G:3YnzlJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiNj65NVch|ryPMX2yN|Y3QDR2MR?=
16HBEMmrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnL5O|IhcA>?MUnEUXNQMX\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKDF4SFLFJINmdGy|IHX4dJJme3Orbnege4lt\CC2eYDlJGVITlJid3n0bEBKSzVyIH;mJFEvPjBzIN88US=>NGXCVmozOzd7MkOxPC=>
16HBENEXoTJRHfW6ldHnvckBCe3OjeR?=MnjkNVAxKM7:TR?=Mkm1NVUxKG2rbh?=NGHQXWtFVVORNUD6OJR6UW6mdXP0bY9vKG:oIH7peJJq[yCxeHnk[UBxem:mdXP0bY9vKGmwIHj1cYFvKDF4SFLFJINmdGy|IHX4dJJme3Orbnege4lt\CC2eYDlJGVITlJ?M4f6eVI{Pzl{M{G4
A549MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mnn0O|IhcA>?Ml73SG1UVw>?NHfIU25CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JJdqdGRidInw[UBGT0[UL3utVoF{KGSncHXu[IVvfCCqdX3hckBCPTR7IHPlcIx{KHerdHigTWM2OCCxZjC0MlYzPiEQvF2=NH3UZXAzOzd7MkOxPC=>
SH-SY5YMVPDfZRwfG:6aXOgRZN{[Xl?NUnMXZZNPzJiaB?=MnLRTWM2OD1zOD6yNUDPxE1?NFzrW4UzOzh5MUmwPS=>
LoVoMYDLbY5ie2ViQYPzZZk>MnPnNkAhcA>?NHK1dWhFVVORM1zSdGlvcGmkaYTpc44hd2ZiRVfGVkBxcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwME[yJO69VQ>?M3zTOFI{QTNyOUm0
PC9M1HGNGtqdmG|ZTDBd5NigQ>?NVjXU2hUOiCqNUTTTmpsTE2VTx?=MkfxTY5pcWKrdHnvckBw\iCHR1\SJIV5d25iMUmg[IVt\XSrb36gZYN1cX[jdHnu[{BufXSjboSgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIGDDPUBk\WyuczD3bZRpKEmFNUCgc4YhOC5yMEi3JO69VQ>?M4iySFI{QTNyOUm0
HCC827NXnxdWZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1v0OlczKGh?M{Gw[GlEPTB;MD6wNVIh|ryPNFPEOIwzOzl5M{G2PC=>
A549MX7LbY5ie2ViQYPzZZk>M1TtRVEh|ryPNF3BOY0yKGh?NHfy[mtFVVORMmDlTY5pcWKrdHnvckBw\iCHR1\SJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNFM6QSEQvF2=M{HPSFI{QTh6M{W0
A549M1K3UmZ2dmO2aX;uJGF{e2G7Moq2NUDPxE1?M4CySFEhcA>?MUHEUXNQM1HUSWNmdGy3bHHyJJVxfGGtZR?=Mn[zNlM6QDh|NUS=
HCC827MoTDT4lv[XOnIFHzd4F6NVq2OVY2OC53IN88US=>MonTNkBpNVO5Z4dkTE2VTx?=MnvXTY5pcWKrdHnvckBw\iCHR1\SJJBpd3OyaH;yfYxifGmxbjDpckBo\W[rdHnubYIuemW|aYP0ZY51KGi3bXHuJGhESzh{NzDj[Yxtew>?M{OzdVI{QTl|M{K4
HCC827M4TPVWZ2dmO2aX;uJGF{e2G7MWSwMlUh|ryPMWqyJIg>MmGwSG1UVw>?MXLJcohq[mm2aX;uJI9nKGNvTXX0JJBpd3OyaH;yfYxifGmxbjDpckBo\W[rdHnubYIuemW|aYP0ZY51KGi3bXHuJGhESzh{NzDj[Yxtew>?NHr3cpIzOzl7M{OyPC=>
HCC827NXHaVnVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFnnc4IyOCEQvF2=NHu3fJg4OiCqM{O2Z2ROW09?M{LxeWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4Sg[4VncXSrbnniMZNmdnOrdHn2[UBpfW2jbjDIR2M5OjdiY3XscJMhcGG{Yn;ybY5oKEWJRmKgSVc1PiC2bzDBO|UxKGSnbHX0bY9vKHerdHigTWM2OCCxZjCwMlAxPThzIN88US=>M2Twc|I1ODV|Nke0
A431MkDDT4lv[XOnIFHzd4F6MmO3NVAxKM7:TR?=M123OFMxKG2rbh?=NICyVFdKdmirYnn0bY9vKG:oIFXHSnIhcW5ic3jl[EBu\W2kcnHu[UB3\XOrY3zld{B4cXSqIFnDOVAhd2ZiMT6xJO69VQ>?M4PWTlI1ODl2NEOy
BCRP-MDCK2MnfpSpVv[3Srb36gRZN{[Xl?M2D6elEvQCEQvF2=M{LzblczKGh?MlqzSG1UVw>?M3LDOGlv[3KnYYPlJI9nKHCuYYPtZUBu\W2kcnHu[UBmgHC{ZYPzbY9vKG:oIFLDVnAh\XiycnXzd4lv\yC{ZYDvdpRmeiCpZX7lJGdHWA>?NVTDb2dXOjRzOESyNVM>
BCRP-MDCK2M13kTmZ2dmO2aX;uJGF{e2G7NYfT[45kOS56IN88US=>MnnjO|IhcA>?M4ftOmROW09?Mof4VoVlfWO2aX;uJI9nKHCuYYPtZUBu\W2kcnHu[UBmgHC{ZYPzbY9vKG:oIFLDVnAh\XiycnXzd4lv\yC{ZYDvdpRmeiCpZX7lJGdHWA>?MWWyOFE5PDJzMx?=
MDCKMnLuR5l1d3SxeHnjJGF{e2G7NF\XVG84OiCqMnjzSG1UVw>?MlPCS2k2OD1zLkS1JO69VQ>?MYqyOFE5PDJzMx?=
MDCK2Mn62SpVv[3Srb36gRZN{[Xl?NUDhSnc5OS56IN88US=>NXXMfINpPzJiaB?=MYnEUXNQMX\Jcohq[mm2aX;uJI9nKGi3bXHuJGJEWlBiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJGhw\WOqc4SgN|M{PDJiYXPjeY12dGG2aX;uJJdqfGhiSVO1NEBw\iB|LkG5JO69VQ>?MWCyOFE5PDJzMx?=
A431MXrDfZRwfG:6aXOgRZN{[Xl?NF;FemQ4OiCqMmPUSG1UVw>?MnjqR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVQ{OSClZXzsd{BmgHC{ZYPzbY5oKEWJRmKge4l1cCCLQ{WwJI9nKDBwNUWg{txONFfTbWwzPDRzMUGyNy=>
Calu3MULDfZRwfG:6aXOgRZN{[Xl?MXu3NkBpM3;2cmROW09?MmfOR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR4FtfTNiY3XscJMh\XiycnXzd4lv\yCKRWKyJJdqfGhiSVO1NEBw\iByLkm5JO69VQ>?M4T1RlI1PDFzMUKz
KBMXzLbY5ie2ViQYPzZZk>NXzIS5h5OTBizszNNXyycYE1OSCqM3nFd2ROW09?MlzzTY5pcWKrdHnvckBw\iCHR1[td5RqdXWuYYTl[EBifXSxcHjvd5Bpd3K7bHH0bY9vKG:oIFXHSnIhf2m2aDDJR|UxKG:oIECuNFI2KM7:TR?=MmT1NlQ1OTFzMkO=
BEAS2BMXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXG1NEDPxE1?NGHpVJI4OiCqNWPtWGpQTE2VTx?=MYXJR|UxRTF|Lkm0JO69VQ>?M2q4O|I1PjB5NUmx
NCI-H1975M1vlR2Z2dmO2aX;uJGF{e2G7MV6xNFAh|ryPM3nPTVE2OCCvaX6=MmPpSG1UVw>?M4r0U2lv\HWldHnvckBw\iCQTzDwdo9lfWO2aX;uJIlvKGi3bXHuJG5EUS2KMUm3OUBk\WyuczDoZZJjd3KrbnegSWdHWiCOOEW4Vk9VPzlyTTDteZRidnR?NHj3WWkzPDZyN{W5NS=>
HelaMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXyyOEBpM13ZXmROW09?MWTJR|UxRTJwNkeg{txONFzBVWQzPDd|MUK4NS=>
HepG2NHL4doxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVW0ZVNqOjRiaB?=NWPSd5ZjTE2VTx?=MX;JR|UxRTZwNEKg{txOMXKyOFc{OTJ6MR?=
Sf9M370fmtqdmG|ZTDBd5NigQ>?Ml[xNVAhdWmwM3W5ZmROW09?NYrnO4lXUW6qaXLpeIlwdiCxZjDheZRweGixc4Doc5J6dGG2aX;uJI9nKHKnY3;tZolv[W62IHjpd{11[WepZXSgSWdHWiBqYX3pco8h[WOrZDC2OFUuOTF6Njmg[ZhxemW|c3XkJJdqfGhiSVO1NEBw\iByLkCyJO69VQ>?MXuyOFc{OTJ6MR?=
SW620NWfzdIdNS3m2b4TvfIlkKEG|c3H5NIDKZZM1QCCqMnq3SG1UVw>?MmPCTWM2OD1{OD6yJO69VQ>?M1PTT|I1QTByNUm0
HCC827MXfGeY5kfGmxbjDBd5NigQ>?NIjUXFMxNjVizszNNV7NZ5lvOiCqM1PCRmROW09?MXzkc4V{KG6xdDDpcohq[mm2IHOtUYV1KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhSUuWIIDoc5NxcG:{eXzheIlwdg>?NF:xeGQzOzl7M{OyPC=>
HCC827MVvGeY5kfGmxbjDBd5NigQ>?NUfseYhEOC53IN88US=>NInNTIIzKGh?NGTOb2ZFVVORMXLkc4V{KG6xdDDpcohq[mm2IHOtUYV1KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YheDR2L{SyJJBpd3OyaH;yfYxifGmxbh?=Ml3hNlM6QTN|Mki=
HCC827M17wVmN6fG:2b4jpZ{BCe3OjeR?=NGjJRngxNjVizszNMWC3NkBpNXXUbHBUTE2VTx?=NHv3R5Vp[XNibn:gZ5l1d3SxeHnjbZR6M2j0OVI{QTl|M{K4
NCI-H1975MlLhSpVv[3Srb36gRZN{[Xl?MV:xNEDPxE1?NVjYeXZxQCCqNH\5e3VFVVORNYm2TYFq\G:nczDuc5QhcW6qaXLpeIkhTUeIUjDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iRWLLJJBpd3OyaH;yfYxifGmxbh?=NIfXeJAzOzFzNkG2PC=>
A431M1[2Z2tqdmG|ZTDBd5NigQ>?MkPMNUDPxE1?M13aPVEhcA>?NVfMRVZITE2VTx?=NILzXpRp[XNibn:gbZJz\X[ncoPpZoxmKGmwaHnibZRqd25ib3[gSWdHWiCjdYTvdIhwe3Cqb4L5cIF1cW:wMnTxNlQ6ODB3OUS=
LNCaPNFX2RZNHfW6ldHnvckBCe3OjeR?=M4fMfFExKM7:TR?=NFHRfXczcCCxcjC0JIg>M2fCOWROW09?NXjufnJF\G:nczDuc5QhcW6qaXLpeEBifXSxcHjvd5Bpd3K7bHH0bY9vKG:oIHntcZVvd3C3cnnmbYVlKG[uYXeteIFo\2WmIFLtfEBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt|MmDdRXRRMXWxPFY3PzNzMh?=
H1975NWXT[5lmU2mwYYPlJGF{e2G7M4LZc|Eh|ryPMnvWNlQhcA>?MkLFSG1UVw>?NX74Wppl\G:nczDuc5QhcW6qaXLpeEBGT0[UIIDoc5NxcG:{eXzheIlwdiCrbjDoeY1idiCKMUm3OUBk\WyuczDoZZJjd3KrbnegSWdHWiCOOEW4Vk9VPzlyTTDteZRidnR?MYWyOFYxPzV7MR?=
H1975NXn4dHl7TnWwY4Tpc44hSXO|YYm=MX6xJO69VQ>?NHjMWG4zPCCqM{\6eWROW09?NVPIOXNu\G:nczDuc5QhcW6qaXLpeEBGWkticHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKEhzOUe1JINmdGy|IHjhdoJwemmwZzDFS2ZTKEx6NUjSM3Q4QTCPMlGxNlQ3ODd3OUG=
HCC827NUK0PY1kU2mwYYPlJGF{e2G7MnG0NE4yOSEQvF2=MofPNUBpNVzCfpFZTE2VTx?=NHXHS2Vp[XNibn:gbZJz\X[ncoPpZoxmKGmwaHnibZRqd25ib3[gSWdHWiCjc4Pld5Nm\CCjczDy[YNwfmW{eTDv[kBGT0[UIHH1eI9xcG:|cHjvdplt[XSrb36=Mn\kNlQyOjR6OUi=
H1975MWnLbY5ie2ViQYPzZZk>M2\QU|AvOzNizszNMYiyJIg>NFzXOWFFVVORM136TYRw\XNibn;0JIlvcGmkaYSgSWdHWiCOOEW4Vk9VPzlyTTDkc5VjdGVibYX0ZY51KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBCU1RicHjvd5Bpd3K7bHH0bY9vMlL3NlQyOjR6OUi=
H1975NUDCV|J{U2mwYYPlJGF{e2G7NFPtO2wxNjN|IN88US=>Mni3NkBpNXrK[ZloTE2VTx?=M2PZfYRw\XNibn;0JIlvcGmkaYSgSWdHWiCOOEW4Vk9VPzlyTTDkc5VjdGVibYX0ZY51KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBGWkticHjvd5Bpd3K7bHH0bY9vNI\xUFQzPDF{NEi5PC=>
H1975NELmbZVMcW6jc3WgRZN{[Xl?NUfkNJhROC5|MzFOwG0>M4[0dVIhcA>?MX7EUXNQM4TaOYRw\XNibn;0JIlvcGmkaYSgSWdHWiCOOEW4Vk9VPzlyTTDkc5VjdGVibYX0ZY51KHCqb4PwbI9zgWyjdHnvci=>NGOxNGMzPDF{NEi5PC=>
H1975MUXLbY5ie2ViQYPzZZk>MYOwMlEzPSEQvF2=NX[0Umg4OjRiaB?=MoDZSG1UVw>?NXfsO21L\G:nczDuc5QhcW6qaXLpeEBGT0[UIFy4OVhTN1R5OUDNJI12fGGwdDDZNVA3QCCjdYTvdIhwe3Cqb4L5cIF1cW:wNFTwfVMzOjN|OUO0Ni=>
H1975M2P0O2tqdmG|ZTDBd5NigQ>?NXvKWY5vOC53IN88US=>NIjnbnozPCCqMlzTSG1UVw>?NYO0TmYy\G:nczDuc5QhcW6qaXLpeEBGT0[UIFy4OVhTN1R5OUDNJI12fGGwdD3t[YRq[XSnZDDFdosheGixc4Doc5J6dGG2aX;uMY[yNlM{QTN2Mh?=
H1975MXHLbY5ie2ViQYPzZZk>Mm\uNE42KM7:TR?=MoT3NlQhcA>?MUnEUXNQMWDkc4V{KG6xdDDpcohq[mm2IFXHSnIhVDh3OGKvWFc6OE1ibYX0ZY51NW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25?NVTUWWJMOjJ|M{mzOFI>
MIAPaCa2NUSzNnRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2Lv[VIvPSEQvF2=MnPNO|IhcA>?NEDjbIFFVVORNVL4WnZDcGG|IH7vJIdzd3e2aDDpcohq[mm2aX;uNGPnRoEzODR4NkW1OS=>
MIAPaCa2Mni3R5l1d3SxeHnjJGF{e2G7MmPSNUDPxE1?NV[2PY01OTBiZB?=NF7VRmpFVVORMXToZZMhdm9iY4n0c5RwgGmlaYT5JIF{e2W|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJINwdG:weTDmc5Ju[XSrb36=M1yzRlIxPDZ4NUW1
MIAPaCa2M4OxTWFxd3C2b4Ppd{BCe3OjeR?=NELSdHYyOCEQvF2=Ml\LNlRpKG:{IES4JIg>M1;YdGROW09?NYTw[XJM\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppdy=>M1\JXlIxPDZ4NUW1
MIAPaCa2NIPhNFdCeG:ydH;zbZMhSXO|YYm=M4m5[FIxKM7:TR?=MUWyOEBpNXjiRXJUTE2VTx?=MYHkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m|IHHzd4V{e2WmIHHzJINie3Cjc3WgN{Bi[3SrdnH0bY9vMUmyNFQ3PjV3NR?=
EoL-1NUXT[XZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4DNNWlEPTB;NT6xO{BvVQ>?MmXpV2FPT0WU
NCI-H720MlPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1PaR2lEPTB;Mk[uPVIhdk1?NVzSXWpvW0GQR1XS
NCI-SNU-5Mnr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUfaNZVqUUN3ME2yPE4yQSCwTR?=NFzpT5ZUSU6JRWK=
EW-3M3i2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2DybmlEPTB;NE[uNFQhdk1?MkPNV2FPT0WU
HCC2218MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1PHV2lEPTB;NUCuOVkhdk1?MUjTRW5ITVJ?
HuO-3N1NXfHcI4{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWLJR|UxRTV4LkC5JI5OMULTRW5ITVJ?
DBNEHvRohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYDZT|RRUUN3ME22NE46PiCwTR?=NInYXY5USU6JRWK=
HSC-4MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRTZzLkWzJI5ONFzXfXVUSU6JRWK=
DOKNHu1ellIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mlf2TWM2OD17Mz62NkBvVQ>?NH;TeFZUSU6JRWK=
H9MkX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{Htc2lEPTB;MUO3MlIhdk1?M3n3WnNCVkeHUh?=
NCI-H292NULM[|VvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlmzTWM2OD1zNkKuOlYhdk1?MlziV2FPT0WU
HSC-2NWK5NIVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1e3Z2lEPTB;MU[1MlU4KG6PNFjqbZRUSU6JRWK=
LU-65NGjqXlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV:2N5hKUUN3ME2xOlYvPjFibl2=MnvxV2FPT0WU
BV-173MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVzOOYZRUUN3ME2xPFYvPTVibl2=M{jjeXNCVkeHUh?=
LB2241-RCCNVrLWI92T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4PRU2lEPTB;MUm0Mlk{KG6PNYnvVog2W0GQR1XS
KG-1NIPKbXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoPFTWM2OD1{MESuN|Qhdk1?MVXTRW5ITVJ?
CHL-1MmrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkHOTWM2OD1{MEiuOVEhdk1?M1rUV3NCVkeHUh?=
KYSE-140MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYjJR|UxRTJyOT65OkBvVQ>?NWflTXVvW0GQR1XS
DU-145M3\JWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWfJR|UxRTJzOT6wOEBvVQ>?MlHpV2FPT0WU
EW-13MoO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYXJR|UxRTJ{NT6xJI5OMXPTRW5ITVJ?
KYSE-450M3fpfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIDsWWpKSzVyPUK0O{46OiCwTR?=M4\ISXNCVkeHUh?=
CAL-72NHrQfVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2\FemlEPTB;Mk[4Mlc{KG6PMl\4V2FPT0WU
MEG-01M{DuO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVPJR|UxRTJ5Nj63OkBvVQ>?NEnzTpdUSU6JRWK=
HCE-TNWDHN5YzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEeyWnJKSzVyPUK3PU44QSCwTR?=MV7TRW5ITVJ?
NCI-SNU-1NHjsXGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NU\Bd|VVUUN3ME2yPFMvOzJibl2=M3roNnNCVkeHUh?=
CAL-27M3jXNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEHDcopKSzVyPUK4PU4xQCCwTR?=NH3KWVJUSU6JRWK=
BALL-1MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUnJR|UxRTJ7Nz60NkBvVQ>?NH\aPXlUSU6JRWK=
SBC-1NIj2W45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXfmUldnUUN3ME2zNFcvPzlibl2=MlH1V2FPT0WU
CAL-54Mn3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn3xTWM2OD1|MUGuNlMhdk1?MYPTRW5ITVJ?
TI-73NXy0RlhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYnJR|UxRTNzMj63OUBvVQ>?NGP5d2lUSU6JRWK=
P12-ICHIKAWAMlnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4XDTGlEPTB;M{K4MlA3KG6PM363bXNCVkeHUh?=
ACHNM1PwU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUT3N5d{UUN3ME2zN|EvPCCwTR?=Mn[5V2FPT0WU
PC-14MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mo\pTWM2OD1|M{OuOFEhdk1?MmrHV2FPT0WU
HCC1806MlzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHjubpNKSzVyPUOzO{42OSCwTR?=NXK1ZXE2W0GQR1XS
SK-MEL-24NXzCXYw4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnzUTWM2OD1|M{euPFchdk1?MWLTRW5ITVJ?
A4-FukMnr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGmxPG1KSzVyPUO1NE4xOiCwTR?=MUnTRW5ITVJ?
ECC10NEjEdnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWDJR|UxRTN3Mj65OkBvVQ>?Mn;OV2FPT0WU
KASUMI-1MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTN4Nj63N{BvVQ>?NWfhUIkyW0GQR1XS
CAL-33NGPkWIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF22[VlKSzVyPUO3NE46KG6PMn32V2FPT0WU
MDA-MB-175-VIINFnncWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFjldJZKSzVyPUO3PE45QCCwTR?=M1i2SXNCVkeHUh?=
NUGC-3NF;qOFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXLIVpZJUUN3ME20NFEvQDFibl2=NUXEeolZW0GQR1XS
KY821MofBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIi4N5pKSzVyPUSwPE42PyCwTR?=M{PMfHNCVkeHUh?=
CTB-1NWrSOmhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUjJR|UxRTR{ND60JI5OM{\1bXNCVkeHUh?=
DoTc2-4510NYHNZpc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHnMZ3ZKSzVyPUS0Nk4yOiCwTR?=NWP2R29wW0GQR1XS
EFO-27NIjld3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnjlTWM2OD12NUSuO|Qhdk1?NYr6bXpnW0GQR1XS
BPH-1NFL5W|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVrrfYh[UUN3ME20PVEvOTZibl2=M32wV3NCVkeHUh?=
KYSE-270NVzGd4VmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MW\JR|UxRTR7OD62OUBvVQ>?Mn35V2FPT0WU
HO-1-N-1MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXvJR|UxRTVyOT6yOUBvVQ>?M1jzcXNCVkeHUh?=
SK-MEL-1M4DYOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlvaTWM2OD13MUCuPVkhdk1?NIC3SJNUSU6JRWK=
MOLT-13MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHG1OZRKSzVyPUWxOE45OiCwTR?=NGrH[FlUSU6JRWK=
TK10MkjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2jjRWlEPTB;NUG1MlEyKG6PM1LH[XNCVkeHUh?=
HNNXHNcYZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NITRflJKSzVyPUWxO{4{QCCwTR?=NUm2Umo4W0GQR1XS
SCC-15NFOzcW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mo\LTWM2OD13MkWuOlghdk1?MnzzV2FPT0WU
NCI-H358NUj1VnlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX;sV4hQUUN3ME21NlcvPjZibl2=MlPEV2FPT0WU
KYSE-180MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUC0Sm9jUUN3ME21N|AvPjJibl2=MWnTRW5ITVJ?
NCI-H82NEP4ZmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4XBXmlEPTB;NUSwMlUhdk1?M2nnUnNCVkeHUh?=
NB7NF3LdnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVGzZ2xUUUN3ME21OFYvOzJibl2=NGW2b2xUSU6JRWK=
DSH1MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{nrNWlEPTB;NU[2Mlg5KG6PMnSyV2FPT0WU
RS4-11M4LGRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX71VWY3UUN3ME21OlgvPTlibl2=M2PGSHNCVkeHUh?=
CANNVXnbHp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlzoTWM2OD13OECuO|Yhdk1?Mn\0V2FPT0WU
Ca9-22MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX3ifJpsUUN3ME21PFgvPjRibl2=MY\TRW5ITVJ?
CAL-39M2jve2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYjFNHhCUUN3ME21PVYvOyCwTR?=NU\zT4FDW0GQR1XS
NCI-H1623M3nzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXPJR|UxRTV7OT6zOkBvVQ>?MXzTRW5ITVJ?
FADUM4jKNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn;TTWM2OD14MESuOlkhdk1?MXrTRW5ITVJ?
NB69NYnne25{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWTJR|UxRTZzND6zOUBvVQ>?MWjTRW5ITVJ?
Ramos-2G6-4C10MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmXNTWM2OD14MkGuOFYhdk1?NGm3SWRUSU6JRWK=
LB1047-RCCM{ewV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTZ{NT6yPUBvVQ>?MVTTRW5ITVJ?
MV-4-11NHnJeJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoHyTWM2OD14MkeuO{BvVQ>?MmPpV2FPT0WU
DBTRG-05MGNIXK[5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUHJR|UxRTZ|Mj6yPEBvVQ>?M{W4S3NCVkeHUh?=
ME-180MoTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHm0WmhKSzVyPU[zNk46KG6PNEPBWYdUSU6JRWK=
NBsusSRNXm3clA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFXad3RKSzVyPU[0Ok42OiCwTR?=MlLpV2FPT0WU
COR-L105NXXXWJl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn3rTWM2OD14NkKuOVMhdk1?NIS0UZZUSU6JRWK=
ETK-1Ml30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MorlTWM2OD14NkKuOVkhdk1?MYrTRW5ITVJ?
L-363MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnjoTWM2OD14N{GuPVQhdk1?MWTTRW5ITVJ?
LU-134-AM4\RSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFvhd4pKSzVyPUexPU4xQSCwTR?=M1H1enNCVkeHUh?=
NCI-H1770NX;RPHk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVS0SXRSUUN3ME23NlIvPCCwTR?=NHTiVYVUSU6JRWK=
HAL-01M3H4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1HwXmlEPTB;N{O0MlcyKG6PMYrTRW5ITVJ?
COLO-684MojoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHnxOWdKSzVyPUe1N{4xOSCwTR?=MVXTRW5ITVJ?
TE-6M371U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEOybFRKSzVyPUe2OE4{OSCwTR?=MYjTRW5ITVJ?
A431Mnr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRTd6MD6wOEBvVQ>?NHH4R|JUSU6JRWK=
LU-135NUPnepVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NE\DfIFKSzVyPUe4N{4xOyCwTR?=NFf2V4RUSU6JRWK=
EC-GI-10M3jsOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV;WTIoyUUN3ME23PFgvPTJibl2=MWLTRW5ITVJ?
TE-12M4rsNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4jCSGlEPTB;OEKxMlEyKG6PMUnTRW5ITVJ?
LoVoM2HUemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoDXTWM2OD16NUmuNFYhdk1?MmjJV2FPT0WU
23132-87MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXLJR|UxRTh4ND6yPEBvVQ>?NIrUdVBUSU6JRWK=
AU565NGm0R2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWXJR|UxRTh4OT62JI5ONHm4XY1USU6JRWK=
DELMnfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGPZWZNKSzVyPUi3O{43PSCwTR?=M4HFW3NCVkeHUh?=
COR-L88MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{L4[2lEPTB;OEiyMlI3KG6PM2HYXnNCVkeHUh?=
NCI-H2126M3fMXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYfJR|UxRTh6Mj64N{BvVQ>?MVvTRW5ITVJ?
CAPAN-1NWjNPFJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHTmSHNKSzVyPUi4N{4zQSCwTR?=MoT3V2FPT0WU
BT-474M3PxZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVHJR|UxRTl|OD6xOEBvVQ>?NVfqUHBFW0GQR1XS
BHYNGD0fplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1PMW2lEPTB;OUe1MlQ5KG6PNYjXWpFTW0GQR1XS
HT-3MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2eyOGlEPTB;OUiyMlQyKG6PMXPTRW5ITVJ?
SK-NEP-1NVnNVVNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV7penVEUUN3ME25PFkvPDRibl2=NVfNTJNPW0GQR1XS
MS-1M4\vTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mke4TWM2OD17OUSuOlkhdk1?MYLTRW5ITVJ?
DOHH-2MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXfJR|UxRTFwMECwNlEh|ryPMnLWV2FPT0WU
NCI-H1304MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3zlV2lEPTB;MT6wNVY1OyEQvF2=MXjTRW5ITVJ?
EM-2NHXpdHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml34TWM2OD1zLkCzNFE3KM7:TR?=NXLFc3oxW0GQR1XS
MHH-PREB-1MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYrJR|UxRTFwMEi0OVEh|ryPMWfTRW5ITVJ?
KU-19-19MmHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mke0TWM2OD1zLkC4OVQyKM7:TR?=MYDTRW5ITVJ?
NCI-H1648MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4nxWGlEPTB;MT6xNFYyPiEQvF2=Ml7DV2FPT0WU
MKN1M3HuZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYTJR|UxRTFwMkG5PFch|ryPMl3pV2FPT0WU
SNU-449NH7NS5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXPJR|UxRTFwMkKyNFgh|ryPMUfTRW5ITVJ?
OAW-42MkfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXLhelk5UUN3ME2xMlI4QDJ3IN88US=>MXnTRW5ITVJ?
769-PMkP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn31TWM2OD1zLkK3PVE5KM7:TR?=MXvTRW5ITVJ?
SW1088NUTvUYw2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFfJfFBKSzVyPUGuNlk3ODdizszNMWfTRW5ITVJ?
GCIYNYDZ[IpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH3MU3RKSzVyPUGuN|AyOzJizszNNX\LVIwzW0GQR1XS
CTV-1M3e2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVTJR|UxRTFwM{C4JO69VQ>?NXm5fmJ2W0GQR1XS
NCI-H1092MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUPxdpZlUUN3ME2xMlMxQDVizszNM13J[XNCVkeHUh?=
NKM-1MlPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{XWc2lEPTB;MT6zNlU6PyEQvF2=MU\TRW5ITVJ?
NCI-H1650M3;nUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIDTU5RKSzVyPUGuN|M1QDJizszNNV2xZWJUW0GQR1XS
SW954M2nZT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{fNemlEPTB;MT6zOFA1QCEQvF2=M2P0T3NCVkeHUh?=
SW48MnvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYTJR|UxRTFwM{[2NVgh|ryPM2j6bHNCVkeHUh?=
SK-N-DZM33vdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1uwO2lEPTB;MT6zOlk1PyEQvF2=NWW1VoM6W0GQR1XS
KMOE-2MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHvPO4JKSzVyPUGuN|k5OTVizszNNFOxTVBUSU6JRWK=
NB5MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYPzVWZFUUN3ME2xMlQxQDl2IN88US=>MnHSV2FPT0WU
CCRF-CEMNWLJOpRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1XBXmlEPTB;MT60NVEyKM7:TR?=MVfTRW5ITVJ?
RH-1NGPzOJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVvJR|UxRTFwNEGxN|Yh|ryPNU\jO|R1W0GQR1XS
NCI-H526NVTNWItQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYO0dlVHUUN3ME2xMlQ{QDJ4IN88US=>MnvoV2FPT0WU
697M{DsV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlfUTWM2OD1zLkS0NVA1KM7:TR?=MX3TRW5ITVJ?
J82NETZOm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYLJR|UxRTFwNEW3OlYh|ryPMUnTRW5ITVJ?
BE-13MoiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NInDRnFKSzVyPUGuOVA3PzFizszNNICyWG1USU6JRWK=
SASMoLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mnf1TWM2OD1zLkWxOlIzKM7:TR?=M4OycXNCVkeHUh?=
SCC-25NE\qTlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkTZTWM2OD1zLkWyN|IzKM7:TR?=NVvaWIZTW0GQR1XS
LAMA-84NWe1XmNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXHFWGVMUUN3ME2xMlU{QDF3IN88US=>MVvTRW5ITVJ?
HSC-3NXnaWJJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIP1VHRKSzVyPUGuOVQ{QCEQvF2=MlS2V2FPT0WU
BT-549M3n0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{PiTWlEPTB;MT61PFc1PyEQvF2=M2HrZ3NCVkeHUh?=
ML-2MkDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkfVTWM2OD1zLk[0NFI6KM7:TR?=M{LVOXNCVkeHUh?=
BB30-HNCMmX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mm\lTWM2OD1zLk[4PVczKM7:TR?=MVvTRW5ITVJ?
PANC-03-27NGn6TVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV;JR|UxRTFwN{CxN|kh|ryPNV7lepR6W0GQR1XS
COLO-678MoTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MonUTWM2OD1zLkezOFQ1KM7:TR?=M3WzfHNCVkeHUh?=
NCI-H1666M2j5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFXLNFFKSzVyPUGuO|Q4ODRizszNNEXFbmNUSU6JRWK=
NCI-H209NVe4fIdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3rBN2lEPTB;MT63O|I3QSEQvF2=MlvGV2FPT0WU
EPLC-272HNF\BPWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIjIUHRKSzVyPUGuPFU2PDlizszNNXfX[WZzW0GQR1XS
OMC-1M2mxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlXtTWM2OD1zLkm5PFg5KM7:TR?=NWDsZmluW0GQR1XS
HCC70NUTScFNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3XsTGlEPTB;Mj6wNFgyPSEQvF2=NWr1S|I3W0GQR1XS
CAL-12TMormS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHjIVmRKSzVyPUKuNFE5PjFizszNNYPVXFl1W0GQR1XS
TGBC24TKBMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4PnbWlEPTB;Mj6wNlk3OSEQvF2=MX7TRW5ITVJ?
EKVXMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3;YWWlEPTB;Mj6wOFk{QSEQvF2=NFvZdllUSU6JRWK=
SW1116MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXj0RVNQUUN3ME2yMlA3ODB7IN88US=>M33RO3NCVkeHUh?=
NCI-H2009NEDhb|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYLJR|UxRTJwME[yNVQh|ryPMYfTRW5ITVJ?
RPMI-8866MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3vUbGlEPTB;Mj6wPFQ5OSEQvF2=NF7VSG1USU6JRWK=
KARPAS-45NFzReGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH;ZcYhKSzVyPUKuNVI1PzlizszNMn;iV2FPT0WU
RXF393MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFTvTHVKSzVyPUKuNVMxOzZizszNMkC4V2FPT0WU
786-0NYDHZ|F[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3juNWlEPTB;Mj6xPFQxPiEQvF2=NWrwOI4yW0GQR1XS
SCC-4MkDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVrVSHVSUUN3ME2yMlIyPzd4IN88US=>MnjNV2FPT0WU
BT-20MlLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGXuSYlKSzVyPUKuNlY4PDRizszNNX7C[VZxW0GQR1XS
A498NYrTbXF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnTnTWM2OD1{LkK5OFE2KM7:TR?=NGKzZWZUSU6JRWK=
IGROV-1MknMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX\JR|UxRTJwM{GyN|ch|ryPM1\pV3NCVkeHUh?=
JVM-3NGrq[|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGjnUINKSzVyPUKuN|Q3PDNizszNM{LGSHNCVkeHUh?=
NCI-H2170NGHVT5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF7QZXJKSzVyPUKuN|Q4QDNizszNNFvQSmJUSU6JRWK=
EW-18MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M33qdmlEPTB;Mj6zOVQ4OSEQvF2=NYDLRmZHW0GQR1XS
KU812NILr[JpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF;ZbWxKSzVyPUKuN|Y4PzlizszNMX7TRW5ITVJ?
NYNILFSHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn:2TWM2OD1{LkO3Nlch|ryPNH;3eWZUSU6JRWK=
HTC-C3NYTK[lBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoD2TWM2OD1{LkSyNlY4KM7:TR?=M4WzOHNCVkeHUh?=
CFPAC-1NF\nO4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUO4dHdlUUN3ME2yMlQ{QDZ2IN88US=>MWnTRW5ITVJ?
HHNXSwc2tTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1f2cGlEPTB;Mj60PVg2PCEQvF2=MUDTRW5ITVJ?
MKN7M2LCfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4r3eGlEPTB;Mj62Nlc1QCEQvF2=MnuxV2FPT0WU
TE-8NYGyU5loT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NW\YOXNiUUN3ME2yMlY{PjV|IN88US=>NGLQUG1USU6JRWK=
MC-IXCNFS0V4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1nPU2lEPTB;Mj62OFQ2OyEQvF2=M1O1WHNCVkeHUh?=
DMS-79Mn2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1HlW2lEPTB;Mj62PVI5PCEQvF2=MkHNV2FPT0WU
Detroit562MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIrkVYRKSzVyPUKuOlk5PDVizszNNW\nR|JPW0GQR1XS
HuP-T4NWD6b2VwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWXhc|dpUUN3ME2yMlczQDF6IN88US=>M{C3ZnNCVkeHUh?=
QIMR-WILMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVjJR|UxRTJwN{W5OVIh|ryPNVrtNXNYW0GQR1XS
BB65-RCCNELM[GVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3nxfGlEPTB;Mj64NFcyOyEQvF2=MoLvV2FPT0WU
PC-3NG\tc|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH7UZ2hKSzVyPUKuPFM{OTdizszNM4Lvc3NCVkeHUh?=
OVCAR-3MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWnJR|UxRTJwOEW1PVQh|ryPNVzvbGx3W0GQR1XS
KYSE-510M2[0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVTJR|UxRTJwOE[3PFYh|ryPMUXTRW5ITVJ?
HC-1NYnPSYJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3mzXGlEPTB;Mj65OFAyOiEQvF2=MYDTRW5ITVJ?
NCI-H1693NHPJTGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVnJR|UxRTJwOUW4PVch|ryPMWnTRW5ITVJ?
DU-4475NHWyUXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHG1coNKSzVyPUKuPVkxPTJizszNMWTTRW5ITVJ?
COLO-680NNVe0VmxtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYjRbWtbUUN3ME2zMlAxPDl3IN88US=>MkPHV2FPT0WU
MN-60NGnLbllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NU\NdYpwUUN3ME2zMlA1QTd2IN88US=>NHvj[5NUSU6JRWK=
BCPAPNEnxXoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn7iTWM2OD1|LkC4Nlk2KM7:TR?=MXLTRW5ITVJ?
647-VMlLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mke2TWM2OD1|LkG2NlIh|ryPMXPTRW5ITVJ?
HT-1376MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX3rR45bUUN3ME2zMlIxPTB4IN88US=>MYTTRW5ITVJ?
NCI-H1793NHHOUm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2LEXGlEPTB;Mz6yNVA6QCEQvF2=MY\TRW5ITVJ?
SW1463NVP6TlVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MomzTWM2OD1|LkK2NVkzKM7:TR?=NV\zSnByW0GQR1XS
NCI-H727MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGL4RnFKSzVyPUOuN|g2QDRizszNMV3TRW5ITVJ?
LB771-HNCNV24co5zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{e1[WlEPTB;Mz6zPVEzPiEQvF2=NGnFfmNUSU6JRWK=
D-542MGMoLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXji[Fg{UUN3ME2zMlQ1OjJ{IN88US=>MnGxV2FPT0WU
NTERA-S-cl-D1M3rsTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYHJR|UxRTNwNES5OVch|ryPM2XKbXNCVkeHUh?=
C8166MonNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTNwNE[1NlEh|ryPMVrTRW5ITVJ?
639-VM2LWfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4HoWGlEPTB;Mz61O|c6OiEQvF2=NF3xUVVUSU6JRWK=
TE-1NX3pdXpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn;FTWM2OD1|LkW5NVY6KM7:TR?=NH7HXFFUSU6JRWK=
OAW-28M3HybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUDa[lhZUUN3ME2zMlU6PDJ4IN88US=>M2\BbXNCVkeHUh?=
SK-LU-1NFzzcHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmfoTWM2OD1|Lk[wOlQ2KM7:TR?=MVTTRW5ITVJ?
CaR-1MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHjhOVJKSzVyPUOuOlExPDhizszNMXjTRW5ITVJ?
A2780M3;LTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTNwNkSwPFkh|ryPM{jRSHNCVkeHUh?=
C2BBe1NYG4cpRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2roUmlEPTB;Mz62OFQxPyEQvF2=MkiyV2FPT0WU
SK-MES-1NYjXTFJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXTJR|UxRTNwNkS2NVQh|ryPM4H6dnNCVkeHUh?=
PANC-10-05MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUXJR|UxRTNwN{KwO|Ih|ryPMnf5V2FPT0WU
J-RT3-T3-5MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M17T[GlEPTB;Mz63OVQxPiEQvF2=NXf3V2pOW0GQR1XS
ES4MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYjsT3Z2UUN3ME2zMlgzOjh4IN88US=>MlzSV2FPT0WU
NCI-H28NELEeZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1jycWlEPTB;Mz64Nlk3OSEQvF2=NIXEXI1USU6JRWK=
NCI-H1155NVnHV|dOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlLQTWM2OD1|Lki0NVU6KM7:TR?=M{XjR3NCVkeHUh?=
KURAMOCHIM4mzZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVnJR|UxRTNwOE[wOVYh|ryPMmn5V2FPT0WU
NCI-H69MkT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mk[3TWM2OD1|LkmwNVc5KM7:TR?=M1u4SHNCVkeHUh?=
IST-MES1M4WxUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2f3TWlEPTB;Mz65OFAzQSEQvF2=M3SyZ3NCVkeHUh?=
NH-12MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4nxVGlEPTB;Mz65OFE5PyEQvF2=M1;ZW3NCVkeHUh?=
JVM-2MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUjm[2xLUUN3ME2zMlk1PzV{IN88US=>MUPTRW5ITVJ?
EW-16M3qxSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWDRVmdRUUN3ME2zMlk2PTd5IN88US=>MXPTRW5ITVJ?
NCI-H441NWf0b4pVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4C1XGlEPTB;Mz65O|AyPCEQvF2=NIHh[pBUSU6JRWK=
RCC10RGBMkX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYf6VXFkUUN3ME20MlAyOjR4IN88US=>NUDYdZlQW0GQR1XS
TCCSUPMmi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MofrTWM2OD12LkGxNFUh|ryPNX;tS25tW0GQR1XS
HL-60M1XCR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVzJR|UxRTRwMUKyOFEh|ryPMWXTRW5ITVJ?
EW-11MknKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnjtTWM2OD12LkGzNlYyKM7:TR?=NULEeYhvW0GQR1XS
KARPAS-299M3y2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnTlTWM2OD12LkOxNFE{KM7:TR?=M4rRenNCVkeHUh?=
SNU-C2BNGm5THhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX\JR|UxRTRwM{S2PFYh|ryPNWO4ZXNpW0GQR1XS
LU-139NIPzXW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUHwS2o5UUN3ME20MlM4OjR5IN88US=>NVvMcox[W0GQR1XS
HCC1937NFvxfHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWTJR|UxRTRwM{e5PVMh|ryPNYjrOmRXW0GQR1XS
GR-STNWHYdHFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2ryVmlEPTB;ND60N|E5KM7:TR?=MoruV2FPT0WU
SK-OV-3M3HyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVvKOFBSUUN3ME20MlQ3ODR{IN88US=>NFv5VpJUSU6JRWK=
A172NI[3XItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M17q[WlEPTB;ND61OVUzOSEQvF2=M{TRVHNCVkeHUh?=
NB10MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYnNeoFsUUN3ME20MlU6PzhzIN88US=>M37hb3NCVkeHUh?=
P30-OHKNFfqVJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWTrV|ZFUUN3ME20MlgyQTJ7IN88US=>MVvTRW5ITVJ?
KYSE-520NID5NoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmnBTWM2OD12Lki4NFE5KM7:TR?=MnzVV2FPT0WU
KNS-62MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHHKeI5KSzVyPUSuPVA5ODdizszNMX;TRW5ITVJ?
ES1NV\kemo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml3OTWM2OD12Lkm2NFM2KM7:TR?=NH\GO3BUSU6JRWK=
KOSC-2NXnTb4VDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnLWTWM2OD12Lkm5PVU6KM7:TR?=NW\mdVY1W0GQR1XS
TE-9NGfCOGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWPLSYFuUUN3ME21MlAyPTJ3IN88US=>NHfLc4JUSU6JRWK=
NCI-H1838NULQV2xoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYezRY1TUUN3ME21MlAzODd4IN88US=>NF62WVZUSU6JRWK=
KP-N-YNMlPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NG\yWVJKSzVyPUWuNVI2QTFizszNMlHFV2FPT0WU
ALL-POM{nPVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{KzPGlEPTB;NT6yNlU5PyEQvF2=MUDTRW5ITVJ?
NOMO-1MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NY\FTpcyUUN3ME21MlI{OTd4IN88US=>NGP3SW5USU6JRWK=
CGTH-W-1NGPZUpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV:4SVRGUUN3ME21MlM5PTh2IN88US=>MVvTRW5ITVJ?
ATN-1MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWfJR|UxRTVwNEGxPFQh|ryPMX\TRW5ITVJ?
AGSNGSxcHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXfJR|UxRTVwNEm2NVgh|ryPMnT5V2FPT0WU
SW13M3fufWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnfqTWM2OD13LkWzNlY2KM7:TR?=M2DmWnNCVkeHUh?=
SW1990MoDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnLZTWM2OD13Lk[yNlg2KM7:TR?=M1rqdnNCVkeHUh?=
BFTC-905M3\J[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUjRdnVWUUN3ME21MlY2QDd6IN88US=>M3LhbnNCVkeHUh?=
RMG-INFHPOo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWXJR|UxRTVwNkW5OFIh|ryPMkfLV2FPT0WU
HD-MY-ZM1nOO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWDO[nhGUUN3ME21MlY5PThzIN88US=>NIPJPYVUSU6JRWK=
HCC1187NF62TXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1y2SmlEPTB;NT63NVA{OiEQvF2=MnTyV2FPT0WU
HCC2998MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF60U4xKSzVyPUWuO|E5PzdizszNM1PqPHNCVkeHUh?=
RT-112MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmjDTWM2OD13LkmwNlQ2KM7:TR?=M1myOHNCVkeHUh?=
CAKI-1MknQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV\KOmRjUUN3ME22MlAxQTh3IN88US=>NYjEcnd1W0GQR1XS
HDLM-2NYj5THJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWnzN4lRUUN3ME22MlAyPDh7IN88US=>M1rrU3NCVkeHUh?=
TE-10M4excGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTZwMES4N|Mh|ryPMX7TRW5ITVJ?
KE-37M3rmeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGfVeXNKSzVyPU[uNFczPThizszNMmPhV2FPT0WU
RCM-1MknXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYiyWGdIUUN3ME22MlA4PzF7IN88US=>MlvlV2FPT0WU
MewoMlu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mnn2TWM2OD14LkGxOFg4KM7:TR?=NYTHOWFOW0GQR1XS
L-428MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWfPNIVzUUN3ME22MlE5ODN5IN88US=>NX;CNXh6W0GQR1XS
8-MG-BAM1i3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVzUVFdZUUN3ME22MlE6Ozd7IN88US=>MkTIV2FPT0WU
SK-MEL-28M1yxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2qyTmlEPTB;Nj6yNFk3PyEQvF2=MUPTRW5ITVJ?
VA-ES-BJMUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlvOTWM2OD14LkOwOFYzKM7:TR?=NXnBWW0zW0GQR1XS
CAL-120NGP0c3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTZwNEWxOlIh|ryPMnzEV2FPT0WU
GAMGMkjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHPG[41KSzVyPU[uOVA3OiEQvF2=NV3TPWZqW0GQR1XS
MSTO-221HNGXBd4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mo\yTWM2OD14LkWxNVch|ryPNGC1fmdUSU6JRWK=
GCTMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYTJR|UxRTZwNUOzPFch|ryPMX3TRW5ITVJ?
SH-4NW\uSmllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NILGOWVKSzVyPU[uOVg5PDRizszNM1LLfnNCVkeHUh?=
Calu-3MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlPKTWM2OD14Lk[1OVY5KM7:TR?=NH;5UHBUSU6JRWK=
SK-HEP-1MlzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXO1RmpOUUN3ME22MlcyPzV|IN88US=>NW\4PFM1W0GQR1XS
PFSK-1M4jRcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHzOOHhKSzVyPU[uO|M1PzhizszNNY\BXYhbW0GQR1XS
NB12MlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH\CeopKSzVyPU[uO|g1ODRizszNNVzDeGRlW0GQR1XS
A388MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUjaSZE5UUN3ME22Mlg6PTJizszNM1\vRXNCVkeHUh?=
KLENHPsSolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2rW[2lEPTB;Nj65OlUyPiEQvF2=M3HY[3NCVkeHUh?=
TE-11M2XESGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUS0cHprUUN3ME23MlA1QTZ5IN88US=>MmHHV2FPT0WU
NCI-H2405NVjDbW9mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYfBWlV1UUN3ME23MlA5Ozl|IN88US=>MWjTRW5ITVJ?
OVCAR-4NXnDXVlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnXNTWM2OD15LkG1N|Uh|ryPM1T0SXNCVkeHUh?=
KP-N-YSM13Me2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYfJR|UxRTdwMUixOEDPxE1?NXfETHFZW0GQR1XS
NOS-1NWrEW2JST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV7JR|UxRTdwMkW4Nlgh|ryPMkP1V2FPT0WU
DMS-114MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkPYTWM2OD15LkK5OlMyKM7:TR?=NIPhWYVUSU6JRWK=
NCI-H2030NEHXZXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NITGfolKSzVyPUeuN|M3QThizszNMWnTRW5ITVJ?
HELM1zMemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVTJR|UxRTdwM{e1NlEh|ryPNXu3[|JpW0GQR1XS
CAL-62MmjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFrpTXhKSzVyPUeuN|k5PjZizszNMoPFV2FPT0WU
COLO-668M2DsW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NW\5eGd1UUN3ME23MlQ{QTZ5IN88US=>NVvObllbW0GQR1XS
SKG-IIIaNW[wcYJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFnyeIxKSzVyPUeuOFU{QDFizszNNFHnfJdUSU6JRWK=
HCC1419MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGnCeVBKSzVyPUeuOFY5OzNizszNM1joPXNCVkeHUh?=
OS-RC-2NF[zN2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVvJR|UxRTdwNEm4PVQh|ryPM4rpNXNCVkeHUh?=
COLO-829NUPXOnRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVn5N2pxUUN3ME23MlY3PDZ|IN88US=>Mlv1V2FPT0WU
NB13NGD1XGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFXKclFKSzVyPUeuPFI3PjdizszNNH;CT|VUSU6JRWK=
DK-MGNHThOZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4O3SGlEPTB;Nz64N|IxOSEQvF2=MU\TRW5ITVJ?
SHP-77M123eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3X3UmlEPTB;Nz64OlY2OyEQvF2=MWDTRW5ITVJ?
NCI-H661M1LObmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWTUWIFsUUN3ME24MlA2QDZ5IN88US=>M4fHT3NCVkeHUh?=
AM-38NFvGZVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmHETWM2OD16LkG2Nlgh|ryPNEPvco5USU6JRWK=
VM-CUB-1M2GyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX\JR|UxRThwMUewNlkh|ryPMY\TRW5ITVJ?
KYSE-70MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mnr2TWM2OD16LkG5O|YyKM7:TR?=NFHDNVRUSU6JRWK=
5637M1LrVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVTJR|UxRThwM{GwOVUh|ryPM2jw[HNCVkeHUh?=
TGBC11TKBNEjFO2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYn5fIZmUUN3ME24MlQ3OTZ2IN88US=>NVrFXINkW0GQR1XS
EGI-1M{ThOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXnIZXNOUUN3ME24MlYxODh6IN88US=>M3q3R3NCVkeHUh?=
D-392MGNF3ySJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkfBTWM2OD16Lk[2NlE1KM7:TR?=M3rNbHNCVkeHUh?=
A673MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXrwWHBxUUN3ME24MlY4PjFzIN88US=>MXjTRW5ITVJ?
COLO-792NGfJS2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NITYcplKSzVyPUiuO|Q6PDZizszNMUTTRW5ITVJ?
NCI-H1792M3nLeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{PDZmlEPTB;OD64PFkxOyEQvF2=M2HweHNCVkeHUh?=
LS-1034NUTRXG5rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYrWdVh{UUN3ME24Mlk1PjV{IN88US=>NIHBZVZUSU6JRWK=
D-566MGM37X[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXTJR|UxRTlwMEG4NUDPxE1?NInTcmZUSU6JRWK=
NCI-H226MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXnJR|UxRTlwMEmg{txONHjr[mVUSU6JRWK=
ChaGo-K-1MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEm0XWJKSzVyPUmuNVA2PzlizszNM1;UUHNCVkeHUh?=
NCI-H2228NULUXpJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEjoUFdKSzVyPUmuNVExQDFizszNNV3kNWx1W0GQR1XS
RPMI-8226MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGLkWXdKSzVyPUmuNVE{ODRizszNNIOwfZRUSU6JRWK=
BFTC-909M2jn[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUTJR|UxRTlwMUiyPVch|ryPNH7CUGJUSU6JRWK=
HPAF-IIMlrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmnJTWM2OD17LkKyOVE5KM7:TR?=NYf5cJZ2W0GQR1XS
Capan-2MlO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUDJR|UxRTlwNECxNFkh|ryPMVXTRW5ITVJ?
IA-LMMmPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NE\o[mRKSzVyPUmuOFE6PjZizszNM37q[XNCVkeHUh?=
KP-4NV:yXWVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHPlbYhKSzVyPUmuOFg5OzhizszNNIXxVFNUSU6JRWK=
A101DMmDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUfJR|UxRTlwNUG3NVkh|ryPM1ziVXNCVkeHUh?=
EFO-21MofUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVLFNoxpUUN3ME25MlU5PzN3IN88US=>NHqzVYxUSU6JRWK=
C32M4rMe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV7JR|UxRTlwNkOzOEDPxE1?NYnIVWdEW0GQR1XS
SW837NVXnVZkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEmxU|FKSzVyPUmuPFQ5OiEQvF2=NGPScZhUSU6JRWK=
OCI-AML2Mn36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWPJR|UxRTlwOE[5OkDPxE1?MoTHV2FPT0WU
NCI-H1355MnuwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3H3O2lEPTB;OT65OFA5QCEQvF2=M2\m[HNCVkeHUh?=
NCI-H2342MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NETXSIRKSzVyPUGwMlAyPTVizszNNHzxRWdUSU6JRWK=
A204NFLRWYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXXJR|UxRTFyLkC0OlYh|ryPNYHmOWIyW0GQR1XS
CAL-51MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYT5[opmUUN3ME2xNE4xQDd5IN88US=>M4q4VnNCVkeHUh?=
HCE-4NEPnVXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYPJR|UxRTFyLkGxNlIh|ryPM{n4OXNCVkeHUh?=
NCI-H810NEj1XJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmDZTWM2OD1zMD6xOVk4KM7:TR?=MonNV2FPT0WU
DJM-1NFXje5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGLRTYJKSzVyPUGwMlE4OzJizszNNF3EfYNUSU6JRWK=
SK-UT-1M2PXeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYjJR|UxRTFyLkK1O|Qh|ryPNV\mVHBXW0GQR1XS
U031NVnlOGtUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MojLTWM2OD1zMD6yOlg3KM7:TR?=NWi1UFEzW0GQR1XS
YH-13M2e5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{H1W2lEPTB;MUCuN|A2PyEQvF2=M2fSV3NCVkeHUh?=
K5NIPLeZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlzkTWM2OD1zMD6zN|k2KM7:TR?=MY\TRW5ITVJ?
HEC-1MnrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYTJR|UxRTFyLkSwPFEh|ryPM3;6enNCVkeHUh?=
A2058NFfobFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnjxTWM2OD1zMD61OFkyKM7:TR?=M{nKW3NCVkeHUh?=
SW962MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoHOTWM2OD1zMD62NlA1KM7:TR?=NXm4UZN{W0GQR1XS
VMRC-RCZNFLNR4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWXJR|UxRTFyLk[3OFkh|ryPNUDsVHkyW0GQR1XS
D-336MGMkToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYnZSGt3UUN3ME2xNE44ODB3IN88US=>NVPJXYVEW0GQR1XS
LXF-289MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MW\JR|UxRTFyLke5Olch|ryPNXfuXHhqW0GQR1XS
SW900NFz1W|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF7KcY9KSzVyPUGwMlgzOjhizszNMl\oV2FPT0WU
K-562MmDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV;wfHJmUUN3ME2xNE45Ozl3IN88US=>M{HYbnNCVkeHUh?=
HCC38NFv6[5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVLJR|UxRTFyLkm3NVYh|ryPMX\TRW5ITVJ?
SF-295M4rZXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2KwU2lEPTB;MUCuPVkxOiEQvF2=MXXTRW5ITVJ?
LB831-BLCM4TifWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVPJR|UxRTFzLkK1OVYh|ryPNFLmTHVUSU6JRWK=
FTC-133MnfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWXzUZF1UUN3ME2xNU4{ODhzIN88US=>NXfwclEyW0GQR1XS
HCC1954NI\SV4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn;pTWM2OD1zMT60N|Yh|ryPNHH0dJJUSU6JRWK=
GOTONFjCRpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1vlRWlEPTB;MUGuOVIxPiEQvF2=M3zOeHNCVkeHUh?=
LS-411NMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1nMbWlEPTB;MUGuOlExOSEQvF2=NELHSo9USU6JRWK=
RPMI-7951M2HjWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mor1TWM2OD1zMT62N|Q5KM7:TR?=MlmxV2FPT0WU
NCI-H1299MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MonYTWM2OD1zMT62OlQ4KM7:TR?=NILYNJZUSU6JRWK=
MLMAMWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUXrPIh6UUN3ME2xNU43QTl5IN88US=>MXPTRW5ITVJ?
MMAC-SFMoPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV7GOoJXUUN3ME2xNU44OjV{IN88US=>M1rod3NCVkeHUh?=
UM-UC-3M3TVe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUXJR|UxRTFzLke0NlEh|ryPMXPTRW5ITVJ?
SCC-9Mn;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXLJR|UxRTFzLkixOVEh|ryPNXT2N2R6W0GQR1XS
HOSNGDDOJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3zCPGlEPTB;MUGuPFY5OyEQvF2=NEjRWFVUSU6JRWK=
OE19M3fWbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYfqXFBpUUN3ME2xNU46OzZ5IN88US=>Mnn6V2FPT0WU
Mo-TNYLwR|dsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWTsS3Z4UUN3ME2xNU46PTRzIN88US=>NHOyfXVUSU6JRWK=
CAMA-1M4PZcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXXJR|UxRTF{LkG2N|Mh|ryPNYS2dJRCW0GQR1XS
U-118-MGMVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWDMVWhkUUN3ME2xNk4zPDRzIN88US=>NGHySZJUSU6JRWK=
KS-1MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYDJVHJFUUN3ME2xNk4zQDN{IN88US=>MYjTRW5ITVJ?
JARNUPGd5dYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1XIXGlEPTB;MUKuN|M3QSEQvF2=MVzTRW5ITVJ?
ABC-1NVHu[ZhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MonUTWM2OD1zMj6zOFEh|ryPNFfIelRUSU6JRWK=
DaoyMoDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnL0TWM2OD1zMj60OVQzKM7:TR?=Mni3V2FPT0WU
C3AM{jINGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mk\1TWM2OD1zMj61O|g2KM7:TR?=MnrGV2FPT0WU
GT3TKBNVvlUJpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXHVbJM3UUN3ME2xNk43OzJ5IN88US=>NVHKfHplW0GQR1XS
DMS-273NETjfY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2TOT2lEPTB;MUKuPFY{OyEQvF2=NX\jWpRXW0GQR1XS
G-361M{fLWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTF{LkmxNlkh|ryPMm\PV2FPT0WU
RH-18MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4j1SmlEPTB;MUOuNlk3OiEQvF2=M2L4WHNCVkeHUh?=
SN12CNVnsOId5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG\jRm1KSzVyPUGzMlM5ODhizszNNEWzVlBUSU6JRWK=
NCI-H1993NELDWYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUXHWY81UUN3ME2xN{41Ojh3IN88US=>NV;Pb4NvW0GQR1XS
LOXIMVINYryUYd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4[4U2lEPTB;MUOuOlE2OSEQvF2=NVTISZg6W0GQR1XS
SK-PN-DWMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkXRTWM2OD1zMz64OFI4KM7:TR?=NInQTIlUSU6JRWK=
KALS-1NEHuTm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn\4TWM2OD1zMz64OVI2KM7:TR?=Mn\vV2FPT0WU
LAN-6MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MljxTWM2OD1zND6yOVMh|ryPNX\VU5Z6W0GQR1XS
A549NFzocmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NECycXRKSzVyPUG0MlQ4OTJizszNNEL5U|lUSU6JRWK=
RDNXnlVXFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4\ORmlEPTB;MUSuOFgyOyEQvF2=MUHTRW5ITVJ?
TGBC1TKBMYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEG3cYlKSzVyPUG0MlY3OTVizszNNEO0coNUSU6JRWK=
NCI-H630NF6wZWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYrJR|UxRTF2Lkm0Olch|ryPM2PGd3NCVkeHUh?=
MIA-PaCa-2MkHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWTJR|UxRTF2Lkm2PUDPxE1?M1vGRnNCVkeHUh?=
NCI-H1755NWDnfIExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV75O2FrUUN3ME2xOE46QTV|IN88US=>MYDTRW5ITVJ?
MOLT-4M3frOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFi4eI5KSzVyPUG1MlA1QTdizszNNXnHSJREW0GQR1XS
CW-2NWLFT2NLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUHieVBKUUN3ME2xOU4yPDJzIN88US=>NHnvdWJUSU6JRWK=
COLO-320-HSRMnvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2PDbmlEPTB;MUWuOVMxPyEQvF2=M4jmTHNCVkeHUh?=
UMC-11M2n1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2PSb2lEPTB;MUWuO|UzOyEQvF2=M4jyd3NCVkeHUh?=
MCF7MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkPTTWM2OD1zNT64NVQ2KM7:TR?=MYjTRW5ITVJ?
NCI-H23NUTVXXRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIfCRodKSzVyPUG1Mlg1OzhizszNNWHYRpRKW0GQR1XS
HuCCT1MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1jiXGlEPTB;MUWuPFc1KM7:TR?=MmjYV2FPT0WU
MPP-89NGnxOoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NULkW2Q5UUN3ME2xOU46PDF5IN88US=>NYrEZZF1W0GQR1XS
HT55MnrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlP2TWM2OD1zNT65OFc5KM7:TR?=MVzTRW5ITVJ?
no-11MnzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIXRfGdKSzVyPUG1Mlk3PjNizszNM{CycHNCVkeHUh?=
GP5dMYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{flfGlEPTB;MU[uNlE5PyEQvF2=MlzHV2FPT0WU
BHT-101M3;L[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3nDTGlEPTB;MU[uNlQ{QSEQvF2=NHfHeWpUSU6JRWK=
M059JM{fpTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlexTWM2OD1zNj6yPFQh|ryPM3z0dHNCVkeHUh?=
D-283MEDMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYO3XmxSUUN3ME2xOk41OjB7IN88US=>M3vUdnNCVkeHUh?=
BENMoXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn;rTWM2OD1zNj61NVU2KM7:TR?=MXTTRW5ITVJ?
LB373-MEL-DMmjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV7sWJNjUUN3ME2xOk44OjN{IN88US=>NF3SNHFUSU6JRWK=
MEL-HOMo\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTF4Lki4OVQh|ryPM2LER3NCVkeHUh?=
GI-ME-NMnKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MU\JR|UxRTF4LkmwN|Ih|ryPM{DjdHNCVkeHUh?=
RKOMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn:1TWM2OD1zNz6wO|Q5KM7:TR?=NF3KOoVUSU6JRWK=
MZ2-MELMmnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFnoTJpKSzVyPUG3MlE{OyEQvF2=MWfTRW5ITVJ?
NCI-H1573NEHnPJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXnJR|UxRTF5LkK4NlYh|ryPMYjTRW5ITVJ?
NCI-H1581NXXYPZBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnXyTWM2OD1zNz60OFEyKM7:TR?=MUTTRW5ITVJ?
NCI-H747M{m4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYXyWplLUUN3ME2xO{42Ojl5IN88US=>NWPRS4JQW0GQR1XS
SW1783MoroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUnZZVV{UUN3ME2xO{43PDF3IN88US=>NEHTd45USU6JRWK=
Calu-6NXWwS5NDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnHoTWM2OD1zNz62O|gzKM7:TR?=MojJV2FPT0WU
SF268NWnlZ2s5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFTKc45KSzVyPUG3MlY6PjlizszNNG\jT2xUSU6JRWK=
ES8NX3VV|hVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXPJR|UxRTF5Lki1PVMh|ryPMnzxV2FPT0WU
KM-H2M3;5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFnF[JpKSzVyPUG3Mlk1OTFizszNMUHTRW5ITVJ?
D-502MGMlnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX;JR|UxRTF5Lkm4NFgh|ryPNEj5PIRUSU6JRWK=
HLEMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHXIemVKSzVyPUG4MlMyPDhizszNMWXTRW5ITVJ?
SW982NVK0WHJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2ruUWlEPTB;MUiuOFA4PSEQvF2=MV7TRW5ITVJ?
MDA-MB-361NHXrVpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4TocWlEPTB;MUiuOVU5QCEQvF2=NFHPeoxUSU6JRWK=
NCI-H1563NV;DXmFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mm\6TWM2OD1zOD63NVI1KM7:TR?=MV\TRW5ITVJ?
MFE-280M2K1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{LpPGlEPTB;MUiuO|I6OyEQvF2=M3HpcnNCVkeHUh?=
U251MknhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWTJR|UxRTF6LkezOFch|ryPNF;GTnBUSU6JRWK=
KNS-42NEjmRYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1m1OGlEPTB;MUiuPFAyPSEQvF2=M1TUOXNCVkeHUh?=
U-266NWHWeXJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX7LdlVsUUN3ME2xPE45PjR7IN88US=>M{n6fnNCVkeHUh?=
OVCAR-8MnXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX32UZBGUUN3ME2xPE46Ojd4IN88US=>NHfqZo5USU6JRWK=
MFH-inoNIC3XIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFTrb41KSzVyPUG4Mlk3PjlizszNMn\PV2FPT0WU
D-263MGM2nyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2jNZ2lEPTB;MUmuNFE4OiEQvF2=NYe3U4VPW0GQR1XS
NCI-H1437NWnuc5o{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUTnV|c1UUN3ME2xPU4xPDZ5IN88US=>MX\TRW5ITVJ?
NCI-H1048MnzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{XJXGlEPTB;MUmuNlMzPiEQvF2=NGK5[GVUSU6JRWK=
NCI-H446MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHnyN3RKSzVyPUG5MlM2QDlizszNMo\FV2FPT0WU
NCI-N87M1m1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NY\oPJFuUUN3ME2xPU42QTl{IN88US=>MXTTRW5ITVJ?
WM-115NF;2O5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2[wUWlEPTB;MUmuOlc4PCEQvF2=MoDFV2FPT0WU
HuH-7MnXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2HMemlEPTB;MUmuO|QzOSEQvF2=NHfIWHFUSU6JRWK=
NCI-H650MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4\MN2lEPTB;MUmuO|UxQCEQvF2=MmX1V2FPT0WU
TYK-nuM4r0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH;MPWVKSzVyPUG5Mlg{PzhizszNMXfTRW5ITVJ?
BeckerNVz4Wol4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkP3TWM2OD1zOT64OVQ4KM7:TR?=NYOwdYxKW0GQR1XS
BB49-HNCMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlvJTWM2OD1zOT65NkDPxE1?NHq3do5USU6JRWK=
HGC-27NH:xeFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF\Sc2dKSzVyPUKwMlE{QTRizszNMn;NV2FPT0WU
SiHaNFrmPIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXrsWW1RUUN3ME2yNE4{PzF{IN88US=>MkTLV2FPT0WU
LB2518-MELM2n1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlGzTWM2OD1{MD6zO|M6KM7:TR?=MVTTRW5ITVJ?
TE-5NUXCTo86T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2TrcWlEPTB;MkCuO|Q5OiEQvF2=MYTTRW5ITVJ?
IST-SL1NFTINXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1\nUWlEPTB;MkCuO|g4QSEQvF2=M133SHNCVkeHUh?=
A375MnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHrYO3lKSzVyPUKxMlA2PjdizszNMoPoV2FPT0WU
MC116M2TCfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnjCTWM2OD1{MT6wO|I{KM7:TR?=NISw[4hUSU6JRWK=
GI-1NHHGb4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXXjbHdnUUN3ME2yNU4yPyEQvF2=NGHUeVVUSU6JRWK=
HOP-62MmTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{[xW2lEPTB;MkGuNlc5PCEQvF2=NGjm[WdUSU6JRWK=
PA-1MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1PHN2lEPTB;MkGuNlc5PyEQvF2=MnLsV2FPT0WU
HTM4rqd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWTKfmtjUUN3ME2yNU41OzNzIN88US=>MorRV2FPT0WU
HUTU-80NH;Gb|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlTHTWM2OD1{MT60N|M3KM7:TR?=MkPQV2FPT0WU
NCI-H1975NGW1bplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHryclhKSzVyPUKxMlQ3OSEQvF2=MXrTRW5ITVJ?
GAKMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXTJR|UxRTJzLkS5PUDPxE1?NU\jZVFPW0GQR1XS
SK-N-ASNX70[HZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFLjVIFKSzVyPUKxMlU3OTlizszNMnHkV2FPT0WU
OE33NXK5Xpp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVzJR|UxRTJzLk[wOFYh|ryPNETGOXZUSU6JRWK=
YKG-1NFP2TpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUjqW5NlUUN3ME2yNU43PTR3IN88US=>NU[wN2Q{W0GQR1XS
CAL-85M{S0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXj0R5VMUUN3ME2yNU46OzB3IN88US=>MVPTRW5ITVJ?
NCI-H2347MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXLJR|UxRTJzLkm0Nlgh|ryPMkHMV2FPT0WU
PANC-08-13NH7scYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEjU[5lKSzVyPUKyMlAyOTlizszNNF3VOnFUSU6JRWK=
SK-N-FIMYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkfOTWM2OD1{Mj6zNFc1KM7:TR?=Ml3MV2FPT0WU
NEC8NHzrbFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHzqUIlKSzVyPUKyMlUxPzhizszNNHXIbVhUSU6JRWK=
AN3-CANY\YR2lRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml;ITWM2OD1{Mj62NFg1KM7:TR?=MnfSV2FPT0WU
HuO9MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXrJdJlXUUN3ME2yNk44Ozl4IN88US=>M{fSeHNCVkeHUh?=
COLO-800NWLwXHJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4DEdmlEPTB;MkKuO|Y2OyEQvF2=NEPufWpUSU6JRWK=
HT-29MkjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkT1TWM2OD1{Mj64PFI{KM7:TR?=NIXSXFFUSU6JRWK=
OC-314NFPEO4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFv1TIRKSzVyPUKyMlg5PDVizszNMnHxV2FPT0WU
G-401Ml2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXTpeWlTUUN3ME2yN{4xPDZ{IN88US=>MUnTRW5ITVJ?
Saos-2Mkj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIfBRXBKSzVyPUKzMlUyQDJizszNMoXVV2FPT0WU
UACC-62MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXTK[YlxUUN3ME2yN{42QDN|IN88US=>Mme1V2FPT0WU
D-247MGMnfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXvHUlVvUUN3ME2yN{44QTN7IN88US=>MX3TRW5ITVJ?
COLO-741NIrDcZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX3IfFk{UUN3ME2yN{46PTZ3IN88US=>MWnTRW5ITVJ?
ES3Mkm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVTJR|UxRTJ2LkCwNlMh|ryPMoPNV2FPT0WU
LNCaP-Clone-FGCM2[5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX3JR|UxRTJ2LkCyNVEh|ryPMlnyV2FPT0WU
SW1710M4D3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mmm5TWM2OD1{ND6xOVA3KM7:TR?=NHfCNHNUSU6JRWK=
LU-99ANV60UYlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYjJR|UxRTJ2LkG4OFEh|ryPM{nacnNCVkeHUh?=
HOP-92MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVTpNmNMUUN3ME2yOE44OjVizszNNV\YZXdTW0GQR1XS
LS-123NW[zVYdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUTWNIhGUUN3ME2yOE46PjF2IN88US=>NH:5SolUSU6JRWK=
T84MlzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MluyTWM2OD1{ND65O|Y2KM7:TR?=MYLTRW5ITVJ?
HCT-116MmPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnPDTWM2OD1{NT60NVg3KM7:TR?=MX7TRW5ITVJ?
M14MnnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4nEfmlEPTB;MkWuOFQ1PyEQvF2=NUHScmhQW0GQR1XS
OCUB-MMYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX7JR|UxRTJ3LkS0OVYh|ryPM3rKNHNCVkeHUh?=
MKN45NVHyeWl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NW\nXWExUUN3ME2yOU43OzF3IN88US=>MXrTRW5ITVJ?
LCLC-97TM1MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1i1WGlEPTB;MkWuO|I5PSEQvF2=NWD4dYVuW0GQR1XS
RVH-421MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXX0dG1yUUN3ME2yOU45OTZzIN88US=>MnLQV2FPT0WU
NKS-81-FDNWHkWoVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVvJR|UxRTJ3LkmwNlEh|ryPM1rUSnNCVkeHUh?=
NCI-H596MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWrDdHhNUUN3ME2yOk4xPDh5IN88US=>MU\TRW5ITVJ?
GB-1MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYG3c4d{UUN3ME2yOk4yQDd7IN88US=>NGDO[2VUSU6JRWK=
ZR-75-30M1TieGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF\xUYtKSzVyPUK2MlIzQTdizszNNGPocnlUSU6JRWK=
U-2-OSNH;oVIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEK0ZlJKSzVyPUK2MlM4PTdizszNMmnxV2FPT0WU
HuP-T3NIqzNVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml[3TWM2OD1{Nj62NVAzKM7:TR?=NIfCUndUSU6JRWK=
MOLT-16NX3LV4dtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXjQOnNbUUN3ME2yOk43OTZ4IN88US=>M{\rNnNCVkeHUh?=
U-87-MGNX[ybZcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2XzPGlEPTB;Mk[uO|Q{QCEQvF2=NYfqdFl3W0GQR1XS
8505CM4Pkbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTJ4LkmxNlYh|ryPNIDBN21USU6JRWK=
SK-MEL-3NXrLXZpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3XnNmlEPTB;Mk[uPVgzQCEQvF2=NGrUdI9USU6JRWK=
COLO-824M3:yZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGe4fYxKSzVyPUK3MlIyQTVizszNMYDTRW5ITVJ?
EW-1NX3XU4V4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWjJR|UxRTJ5LkO1OVQh|ryPMULTRW5ITVJ?
UACC-257MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVHx[HRMUUN3ME2yO{4{QDB2IN88US=>M1OyN3NCVkeHUh?=
Hs-578-TMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYXJR|UxRTJ5LkWyPVkh|ryPNEjrO2pUSU6JRWK=
UACC-893NFLydmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{LzeWlEPTB;MkeuOlY{OSEQvF2=M3rJfHNCVkeHUh?=
MHH-NB-11NYnGZ3dRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWroUIxyUUN3ME2yO{45ODB5IN88US=>M3qwUnNCVkeHUh?=
KYSE-410NEnrNFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVLJR|UxRTJ6LkK3O|kh|ryPMYfTRW5ITVJ?
SF126NHjRZlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4P2c2lEPTB;MkiuO|Q{PSEQvF2=M1rne3NCVkeHUh?=
HT-144MmjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX3yWFljUUN3ME2yPU4{OzZ{IN88US=>NV3Vb|hGW0GQR1XS
SW1573NV3JU5Z4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYjJR|UxRTJ7LkO1NFkh|ryPMkH6V2FPT0WU
SW620NX3xcI1LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnqzTWM2OD1{OT6zOlQyKM7:TR?=MUPTRW5ITVJ?
SCHM2fzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn;CTWM2OD1{OT64PFMyKM7:TR?=MmPSV2FPT0WU
EW-22Ml\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn;STWM2OD1|MD6xPVY6KM7:TR?=NGf1TVhUSU6JRWK=
H4MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX\JR|UxRTNyLkS2OVQh|ryPNEnxdItUSU6JRWK=
CAS-1MkLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1HNT2lEPTB;M{CuO|g2QSEQvF2=NHjjTVRUSU6JRWK=
MG-63M{HJNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnPMTWM2OD1|MD64OFc5KM7:TR?=MnT4V2FPT0WU
MDA-MB-415NIGwT3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFzuTFZKSzVyPUOxMlE4PTNizszNNF6wfHdUSU6JRWK=
NCI-H1395NHi3WJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXLFXmlyUUN3ME2zNU4zOzJ6IN88US=>MmP4V2FPT0WU
Ca-SkiMlj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrJR|UxRTNzLkOxO|ch|ryPMlTlV2FPT0WU
BxPC-3NFfOT|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTNzLkO3Nlkh|ryPNYr2UXc6W0GQR1XS
A3-KAWMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmrxTWM2OD1|MT60OFcyKM7:TR?=MU\TRW5ITVJ?
T-24NIi2dVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmXFTWM2OD1|MT63N|YzKM7:TR?=M{PiR3NCVkeHUh?=
NCI-H2029M{fhSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEPie5NKSzVyPUOxMlc4PjVizszNNGm2fmpUSU6JRWK=
YAPCMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYPJR|UxRTN{LkC0NFch|ryPMXHTRW5ITVJ?
SK-MEL-2M1\5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlK1TWM2OD1|Mj6wOVIh|ryPM{jq[3NCVkeHUh?=
LS-513MlK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGG0dm5KSzVyPUOyMlEyQDdizszNNGHneHhUSU6JRWK=
AsPC-1MonpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYnJR|UxRTN{LkO2NFUh|ryPM{m3bnNCVkeHUh?=
KYSE-150NUTQ[JQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWLJR|UxRTN{LkO3O|Mh|ryPNFjUO|dUSU6JRWK=
NCI-H520M1PMNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnXsTWM2OD1|Mj60OFgzKM7:TR?=M2PKWXNCVkeHUh?=
JEG-3NFztdFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFPDZoFKSzVyPUOzMlA6PzFizszNNXz0cnhEW0GQR1XS
GMS-10NYLCS4lWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHLU[5ZKSzVyPUOzMlMxODRizszNMnriV2FPT0WU
HT-1080NITiemNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEju[W1KSzVyPUOzMlM6KM7:TR?=M1fxZnNCVkeHUh?=
NCI-H1651NWfzWpplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVvJR|UxRTN|LkO5OkDPxE1?NF2zUIxUSU6JRWK=
NCI-H2122M1:wZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVOwR5kyUUN3ME2zN{42PTd2IN88US=>M2DYbXNCVkeHUh?=
ES5MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFnDbpZKSzVyPUOzMlczQTJizszNNHv2Vm1USU6JRWK=
8305CM2\wNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWPRV3RyUUN3ME2zN{46QTN5IN88US=>MmPiV2FPT0WU
KM12NGH6[5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkjhTWM2OD1|ND6wOFc5KM7:TR?=MkTlV2FPT0WU
HCT-15MlG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWjJR|UxRTN2LkGyO{DPxE1?MX;TRW5ITVJ?
OVCAR-5NFHpS4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVz4cJpPUUN3ME2zOE4zOTh{IN88US=>NU\0ZnprW0GQR1XS
NCI-H2291NUn4O5k1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4\HemlEPTB;M{SuNlQ4OiEQvF2=NVLuPYx5W0GQR1XS
CP50-MEL-BNGPMVmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUDidI13UUN3ME2zOE43PTl{IN88US=>MWDTRW5ITVJ?
C-33-AM3vmWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGjFTmxKSzVyPUO0MlY5PTdizszNNI\jOZBUSU6JRWK=
NCI-H2452MlLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUf5cotUUUN3ME2zOE44QDh{IN88US=>NFrMephUSU6JRWK=
MDA-MB-157NVnmXWp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFLWRnRKSzVyPUO0MlgyQTNizszNMlPkV2FPT0WU
LN-405MkS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWjJR|UxRTN3LkSzNFgh|ryPMYPTRW5ITVJ?
MDA-MB-231M{jRd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{XqOGlEPTB;M{WuOVA2PCEQvF2=MnrqV2FPT0WU
EW-24NV\YeFhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEXmWXZKSzVyPUO1MlY{OzVizszNMXzTRW5ITVJ?
MKN28MnW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mk\JTWM2OD1|NT64NlM3KM7:TR?=M2PIcXNCVkeHUh?=
KINGS-1MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnXlTWM2OD1|NT64OFM1KM7:TR?=NIrL[o5USU6JRWK=
LC-2-adMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkXuTWM2OD1|Nj62PVkh|ryPNEnmXnZUSU6JRWK=
IGR-1MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MY\JR|UxRTN4LkewO|Uh|ryPMUDTRW5ITVJ?
SW626NVTJ[FlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1O1OGlEPTB;M{euNFQyPyEQvF2=M4jQR3NCVkeHUh?=
ONS-76M1jzc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUPJR|UxRTN5LkGzNFkh|ryPMYrTRW5ITVJ?
T98GMnPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MULJR|UxRTN5Lki2N|Uh|ryPNV\CZng2W0GQR1XS
NB14M1nRN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVT1VFRiUUN3ME2zPE41PTR2IN88US=>NEnre|RUSU6JRWK=
D-423MGNUW0fW53T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnT5TWM2OD1|OD60PFY6KM7:TR?=MUDTRW5ITVJ?
NCI-H510ANHjYWnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX\reXZPUUN3ME2zPE43PDVzIN88US=>MmL4V2FPT0WU
NMC-G1NEL4RotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFy3O3ZKSzVyPUO4MlczOjJizszNMl34V2FPT0WU
SW948M4PieWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mlr1TWM2OD1|OD64PVQ6KM7:TR?=MVzTRW5ITVJ?
MFM-223MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmnKTWM2OD1|OD65OFMyKM7:TR?=Mnv3V2FPT0WU
PAN1M2e1OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3nsT2lEPTB;M{iuPVkyQSEQvF2=MlrxV2FPT0WU
MZ7-melMYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV33[HpTUUN3ME2zPU4yOTl7IN88US=>MmfWV2FPT0WU
COLO-679MnXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYPJR|UxRTN7Lkm3NFgh|ryPMoC1V2FPT0WU
SW872M2jkPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVXJR|UxRTRyLkKwN|Eh|ryPMV3TRW5ITVJ?
HT-1197MlPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3e3VmlEPTB;NECuNlg3QSEQvF2=NVXld|UzW0GQR1XS
ES6M4foS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NELPWFJKSzVyPUSwMlQ2PTJizszNNV;QNm83W0GQR1XS
SNU-387NXfRWnpGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHTYfpRKSzVyPUSwMlgzOzhizszNMmjPV2FPT0WU
T47DNEjDVpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVrJR|UxRTRzLkCxPVIh|ryPNGHMdmNUSU6JRWK=
G-402NFWwXI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2jXeWlEPTB;NEGuNFgxQSEQvF2=MlvmV2FPT0WU
MZ1-PCMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWnHVYl6UUN3ME20NU45OSEQvF2=MULTRW5ITVJ?
SW1417MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mlm5TWM2OD12Mj6zNFMh|ryPNYfLPYlNW0GQR1XS
RERF-LC-MSNXWwdZNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVjJR|UxRTR{LkWwPFch|ryPNYHqO5BYW0GQR1XS
SF539NGTMSFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NU\jc2RZUUN3ME20Nk42PTJ7IN88US=>NVi0S285W0GQR1XS
ESS-1NFnvWVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NITCSZBKSzVyPUSzMlU2PThizszNMYjTRW5ITVJ?
RO82-W-1MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTR|Lk[xOVMh|ryPM{e2TXNCVkeHUh?=
S-117MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFy4d2pKSzVyPUSzMlY6PThizszNMYPTRW5ITVJ?
SW756MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYHZfpBPUUN3ME20N{45OjR{IN88US=>MWDTRW5ITVJ?
CP66-MELNHP0cmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYLJR|UxRTR3LkexOFMh|ryPMV\TRW5ITVJ?
H-EMC-SSMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFvpdINKSzVyPUS1Mlc3QTNizszNNYjU[IFkW0GQR1XS
NCI-H2052NYOxb3U2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3HPfGlEPTB;NEWuPVAzPyEQvF2=Mo\BV2FPT0WU
SW684M364TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn:yTWM2OD12Nz6wNFgyKM7:TR?=M17WR3NCVkeHUh?=
HCC1569NUPZPIxWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml7zTWM2OD12Nz6xOlU5KM7:TR?=M4myV3NCVkeHUh?=
KGNNIexZ49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFvWWIZKSzVyPUS3MlM{OTFizszNMXPTRW5ITVJ?
LCLC-103HNF\DbnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUPRUod7UUN3ME20O{41PDB2IN88US=>MUXTRW5ITVJ?
SW780M{f6fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHvrXlBKSzVyPUS3MlY{PTFizszNNXfYZ3Z{W0GQR1XS
NCI-H1703NULH[oRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1;ySmlEPTB;NEiuN|M2OiEQvF2=MYjTRW5ITVJ?
HCC1395MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4nW[GlEPTB;NEiuO|Q{OiEQvF2=NYTP[mE{W0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Gefitinib (100 mg/kg) improves the anti-tumor effect of radiotherapy in LoVo tumor xenografts. [3] Gefitinib treatment of nude mice bearing established human GEO colon cancer xenografts reveals a reversible dose-dependent inhibition of tumor growth because GEO tumors resumes the growth rate of controls at the end of the treatment. [4]
Features A potent EGFR tyrosine kinase inhibitor.

Protocol(Only for Reference)

Cell Assay: [1]

Cell lines NR6, NR6M and NR6W cells
Concentrations 0-2 μM
Incubation Time 72 hours
Method Exponentially growing cells including NR6, NR6M, NR6M and NR6W cells are seeded in sextuple in 96-well plates at a concentration of 2000 cells/well, allowed to adhere and subsequently washed in PBS and incubated overnight in medium containing 0.5% FCS. Cells are then treated with varying concentrations (0-2 μM) of Gefitinib or the solute control DMSO and EGF. The optimal EGF concentration for inducing proliferation of NR6wtEGFR and NR6W cells has previously been determined and hence NR6wtEGFR and NR6W cells are supplemented with 10 nM and 0.1 nM EGF, respectively. EGF is not added to NR6 and NR6M cells. After 72 hours the amount of cells are measured by performing a MTT proliferation assay.

Animal Study: [3]

Animal Models Female nude mice (cba nu/nu) aged 8–10 weeks are intra-dermal injected with LoVo cells.
Formulation 0.5% polysorbate
Dosages 100 mg/kg
Administration Once daily by oral administration (0.1 mL/10 g body weight) for 14 days

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Pedersen MW, et al. Br J Cancer. 2005, 93(8), 915-923.

[2] Moasser MM, et al. Cancer Res. 2001, 61(19), 7184-7188.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-05-07)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02740894 Completed Is Targeted Therapy Increasing Survival Inoperable Nonsmall Cell Lung Cancer With Spinal Metastasis ? Taipei Veterans General Hospital, Taiwan February 2016 --
NCT02347839 Recruiting Lung Cancer Sun Yat-sen University January 2016 Phase 2
NCT02588261 Recruiting Non-small Cell Lung Cancer (NSCLC) Astellas Pharma Global Development, Inc.|Astellas Pharma Inc November 2015 Phase 3
NCT02326285 Recruiting Non-squamous Non-small Cell Lung Cancer Stage II|Non-squamous Non-small Cell Lung Cancer Stage IIIA|Non-squamous Non-small Cell Lung Cancer Stage I  ...more Non-squamous Non-small Cell Lung Cancer Stage II|Non-squamous Non-small Cell Lung Cancer Stage IIIA|Non-squamous Non-small Cell Lung Cancer Stage IIIB|Activating EGFR Mutation|NSCLC AIO-Studien-gGmbH|AstraZeneca November 2015 Phase 2|Phase 3
NCT02321293 Recruiting Lung Cancer Lady Davis Institute|Jewish General Hospital August 2015 Phase 1

view more

Chemical Information

Download Gefitinib (ZD1839) SDF
Molecular Weight (MW) 446.90
Formula

C22H24ClFN4O3

CAS No. 184475-35-2
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 89 mg/mL (199.14 mM)
Ethanol 4 mg/mL (8.95 mM)
Water <1 mg/mL (<1 mM)
In vivo 5% DMSO+corn oil 2.5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine

Customer Product Validation (11)


Click to enlarge
Rating
Source Mol Syst Biol 2011 7, 486. Gefitinib (ZD1839) purchased from Selleck
Method qPCR analysis
Cell Lines glioblastoma cell lines
Concentrations 5 μM, 50 ng/ml
Incubation Time 6 h
Results We perturbed the activity of the EGFR by activating it using one of its ligands (EGF) and inhibiting it with a selective EGFR inhibitor (Gefitinib). As readout, we measured the transcriptional effect on SOCS2 (a modulator of STAT signaling), NR2E1(also known as TLX , a transcription factor believed to be important for neural stem cell renewal), yielding results compatible with a coupling between hub perturbation and transcriptional response.

Click to enlarge
Rating
Source Oncogene 2010 30, 737-750. Gefitinib (ZD1839) purchased from Selleck
Method Western blot
Cell Lines MEFs
Concentrations 1 μM
Incubation Time 48 h
Results We found that gefitinib, a specific EGFR inhibitor, almost completely recapitulated the results obtained by genistein (Figure a). Consistent with these results, we observed increased EGFR phosphorylation within 2 days of RECK depletion , with insignificant change in its protein amount (Figure b).

Click to enlarge
Rating
Source Carcinogenesis 2010 31, 1948–1955 . Gefitinib (ZD1839) purchased from Selleck
Method Luciferase assay
Cell Lines LNCaP-AI cells, LNCaP cells
Concentrations 20 μM
Incubation Time 24 h
Results EGF significantly stimulates the promoter activity of sPLA2-IIa gene in both LNCaP and LNCaP-AI cells (shown in LNCaP-AI cells), whereas Gefitinib and other inhibitors all tested downregulated the promoter activity both at the basal level (shown in LNCaP cells) and in response to EGF stimulation (shown in LNCaP-AI cells)

Click to enlarge
Rating
Source Carcinogenesis 2010 31, 1948–1955. Gefitinib (ZD1839) purchased from Selleck
Method ELISA
Cell Lines LNCaP-AI cells
Concentrations 20 μM
Incubation Time 24 h
Results Lapatinib, LY294002 and Bortezomib significantly inhibited sPLA2-IIa secretion, whereas Erlotinib, Gefitinib and CI-1033 had a moderate effect in LNCaP-AI cells .

Click to enlarge
Rating
Source J Immunother 2011 34(4), 372-81. Gefitinib (ZD1839) purchased from Selleck
Method Cytotoxicity assay
Cell Lines NK-92 cells/ lung cancer cells
Concentrations 10 μM
Incubation Time 24 h
Results Susceptibility of lung cancer cells to cytolytic activity of NK cells was significantly increased by treatment with EGFR inhibitors (erlotinib/gefitinib) and was reversed by blocking step using mAb against NKG2D before the assay in all lung cancer cells.

Click to enlarge
Rating
Source Antiviral Res 2010 89, 64-70. Gefitinib (ZD1839) purchased from Selleck
Method Proliferation assay, Plaque reduction test, Western blot, Real-time PCR
Cell Lines Hep2 cells
Concentrations 0.01-1000 μM
Incubation Time
Results While for Gefitinib concentrations between 100 μM and 0.01 μM the proliferation rate was almost 100% of the controls, only at concentrations of 1000 μM a slight (24%) decline in proliferation was observed (Fig.A). IC50 values of Gefitinib for plaque size reduction were calculated by dividing plaque size by total size of one tissue culture plate well for each compound concentration. A non-linear regression fit curve analysis from the calculated values revealed for plaque size reduction an IC50 value of 4.93μM for Gefitinib(Fig. B).The analysis of phosphorylated EGFR and of the downstream signaling kinases ERK1/2 in cell lysates of the assay confirmed the dose dependency of the antiviral effect of Gefitinib. Kinase activ-ities were completely suppressed at concentrations above 1μM as determined by Western blot analysis. VACV proteins were not detectable between 10 μM and 100 μM in Western blot analysis anymore (Fig. C).

Click to enlarge
Rating
Source Antiviral Res 2010 89, 64-70. Gefitinib (ZD1839) purchased from Selleck
Method Immunofluorescence
Cell Lines Hep2 cells
Concentrations 0.01-1000 nM
Incubation Time 96 h
Results As shown in Fig. A, an immunofluorescent staining of a plaque reduction test was performed 96 h after viral infection. VACV infected cells were treated with 1000 μM, 1 μM or 0.01 μM Gefitinib and compared to uninfected cells after 96 h incubation. At concentrations of 1000 μM Gefitinib virus induced plaques were rarely found in cell culture and infected cells only could be identified by fluorescent staining of orthopoxvirus proteins (green) but not by light microscopy. At this Gefitinib concentration EGFR phosphorylation was completely suppressed in the cells and even the uninfected, untreated control cells show a stronger pEGFR signal (control, red). Occasionally found plaques, visible by flourescence microscopy only, showed a very compact shape with minimal disruption in its center. At the lower Gefitinib concentrations plaques showed an increasing number of infected and pEGFR positive cells (merge, yellow) and a surround-ing small zone of solely pEGFR positive cells (red). The lower the Gefitinib concentration the more plaques with a disrupted center were observed (1μM and 0.01μM). Most of the cells localized in the center of the plaque were positive for orthopoxvirus infection but negative for pEGFR ( Fig. B).

Click to enlarge
Rating
Source Mol Biosyst 2011 7, 3223-33. Gefitinib (ZD1839) purchased from Selleck
Method Immunoprecipitation/Western blotting
Cell Lines
Concentrations 5 μM
Incubation Time 0-1 h
Results In the presence of the EGFR tyrosine kinase inhibitor Z D1839 (Iressa) revealed that the observed increase in binding between PCM1 and Azi1 is specific to EGFs timulation and requires E GFR activation.

Click to enlarge
Rating
Source Int J Proteomics 2011 215496. Gefitinib (ZD1839) purchased from Selleck
Method CEER assay
Cell Lines H358 cell line
Concentrations 0.01-10 μM
Incubation Time 4 h
Results HER1 and/or HER2 pathway-activated cell lines, H358 , had their activation blocked by the HER1/2 kinase inhibitors Gefitinib.

Click to enlarge
Rating
Source 2010 Dr. Zhang of Tianjin Medical University. Gefitinib (ZD1839) purchased from Selleck
Method Western blot
Cell Lines Breast cancer cells
Concentrations 0-5 nM
Incubation Time 24 h
Results

Click to enlarge
Rating
Source 2010 Dr. Vicky Tin from University of Hong Kong. Gefitinib (ZD1839) purchased from Selleck
Method MTT assay
Cell Lines H1299 cells, H358 cells, H25 cells, HCC827 cells
Concentrations 0-400 nM
Incubation Time 72 h
Results

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related EGFR Products

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • Afatinib (BIBW2992) Dimaleate

    Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.

  • Poziotinib (HM781-36B)

    Poziotinib (HM781-36B) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Phase 2.

  • Erlotinib HCl (OSI-744)

    Erlotinib HCl (OSI-744) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • Afatinib (BIBW2992)

    Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM in cell-free assays, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.

  • Osimertinib (AZD9291)

    Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.

  • Lapatinib

    Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.

  • AG-490 (Tyrphostin B42)

    AG-490 (Tyrphostin B42) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.

  • Rociletinib (CO-1686, AVL-301)

    Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT in cell-free assays, respectively. Phase 2.

  • AG-1478 (Tyrphostin AG-1478)

    AG-1478 (Tyrphostin AG-1478) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR.

Recently Viewed Items

Tags: buy Gefitinib (ZD1839) | Gefitinib (ZD1839) ic50 | Gefitinib (ZD1839) price | Gefitinib (ZD1839) cost | Gefitinib (ZD1839) solubility dmso | Gefitinib (ZD1839) purchase | Gefitinib (ZD1839) manufacturer | Gefitinib (ZD1839) research buy | Gefitinib (ZD1839) order | Gefitinib (ZD1839) mouse | Gefitinib (ZD1839) chemical structure | Gefitinib (ZD1839) mw | Gefitinib (ZD1839) molecular weight | Gefitinib (ZD1839) datasheet | Gefitinib (ZD1839) supplier | Gefitinib (ZD1839) in vitro | Gefitinib (ZD1839) cell line | Gefitinib (ZD1839) concentration | Gefitinib (ZD1839) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us